JPS6254086B2 - - Google Patents
Info
- Publication number
- JPS6254086B2 JPS6254086B2 JP53161388A JP16138878A JPS6254086B2 JP S6254086 B2 JPS6254086 B2 JP S6254086B2 JP 53161388 A JP53161388 A JP 53161388A JP 16138878 A JP16138878 A JP 16138878A JP S6254086 B2 JPS6254086 B2 JP S6254086B2
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- antibody
- compound
- antitumor
- sarcoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 51
- 239000002246 antineoplastic agent Substances 0.000 claims description 50
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 208000006268 Sarcoma 180 Diseases 0.000 claims description 29
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 26
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 238000001042 affinity chromatography Methods 0.000 claims description 24
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims description 16
- 229960004857 mitomycin Drugs 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 12
- 102000018358 immunoglobulin Human genes 0.000 claims description 12
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 229960002918 doxorubicin hydrochloride Drugs 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 9
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 8
- 108010006654 Bleomycin Proteins 0.000 claims description 8
- 108010092160 Dactinomycin Proteins 0.000 claims description 8
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims description 8
- 229960001561 bleomycin Drugs 0.000 claims description 8
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 8
- 229960000640 dactinomycin Drugs 0.000 claims description 8
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 8
- 229960000975 daunorubicin Drugs 0.000 claims description 8
- ILFPCMXTASDZKM-YFKPBYRVSA-N (1s)-2-methylidene-3-oxocyclopentane-1-carboxylic acid Chemical compound OC(=O)[C@H]1CCC(=O)C1=C ILFPCMXTASDZKM-YFKPBYRVSA-N 0.000 claims description 7
- ILFPCMXTASDZKM-UHFFFAOYSA-N sarkomycin Natural products OC(=O)C1CCC(=O)C1=C ILFPCMXTASDZKM-UHFFFAOYSA-N 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 239000003972 antineoplastic antibiotic Substances 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000009916 Yoshida Sarcoma Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000007864 aqueous solution Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 14
- 230000000259 anti-tumor effect Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000012153 distilled water Substances 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000385 dialysis solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000007758 minimum essential medium Substances 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 208000003455 anaphylaxis Diseases 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 206010002199 Anaphylactic shock Diseases 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- XNPOFXIBHOVFFH-UHFFFAOYSA-N N-cyclohexyl-N'-(2-(4-morpholinyl)ethyl)carbodiimide Chemical compound C1CCCCC1N=C=NCCN1CCOCC1 XNPOFXIBHOVFFH-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex⢠Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000007973 glycine-HCl buffer Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000722 protumoral effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/813—Carrier is a saccharide
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
æ¬çºæã¯ãæ°èŠæè
«çå€ã«é¢ãããã®ã§ãã€
ãŠãæŽã«è©³ããã¯è «çæåã«å¯Ÿããæäœã«æè «ç
å€ãç¹ã«ææ§ç©è³ªç³»æè «çå€ãäŸãã°ãã€ããã€
ã·ã³ïŒ£ãå¡©é žãããœã«ãã·ã³ããã¬ãªãã€ã·ã³ã
ããŠãã«ãã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³ã¶ã«
ã³ãã€ã·ã³ã®ããšãå°ããšãïŒåã®ã¢ããåºãã
ãã¯ã«ã«ããã·ã«åºãæããæè «çç©è³ªåã¯è©²æ
è «çç©è³ªã«çµåå€ãçµåãããç©è³ªãã¢ããåºå
ã¯ã«ã«ããã·ã«åºãä»ããŠçµåãããŠãªãååç©
ãæå¹æåãšããŠå«æããæè «çå€ã«é¢ãããã®
ã§ããã æ¬çºæã¯ãäžèšã®çŽ°èæ¯æ§ã®é«ãæè «çå€ãã
極ããŠç·©åãªæ¡ä»¶äžã§ã¢ãã€ãã€ãã€âã¯ããã
ã°ã©ãã€ãŒã«ãã粟補ãããè «çæåã«å¯Ÿããæ
äœã«ã¢ããçµåïŒâNHCOâïŒã«ãã€ãŠçµåãã
ãæ°èŠãªååç©ã«åºãæè «çå€ã§ãã€ãŠãæè «ç
å¹æã«ããããªãã现èæ¯æ§ã¯ãåæã®ïŒã€ã§ã
ãæè «çå€ã«ããã¹ãŠæ Œæ®µã«äœãæè «çå€ãæäŸ
ããããšãç®çãšããã è¿å¹Žçš®ã ã®æè «çå€ãåºã䜿çšãããŠãæãçš
床ã®å¹æããããŠããããããã®äžã«ã¯åèšã®ã
ã€ããã€ã·ã³ïŒ£ãå¡©é žãããœã«ãã·ã³ããã¬ãªã
ã€ã·ã³ãããŠãã«ãã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ã
ã¶ã«ã³ãã€ã·ã³çããããããããèªèº«ã¯äœãã
é«ã现èæ¯æ§ãæããŠããŠãæäžããéã«çœè¡ç
æžå°ãè±æ¯ãèè žé害çã®å¯äœçšãåããããšã
ç¥ãããŠããããã®çºã«ãããè¬å€ã®äœ¿çšã«é床
ã®ããã®ãå®æ ã§ããã äžæ¹ãããçš®ã®è «çã®æåã«å¯Ÿããæäœã補é
ãŸãã¯åé¢ããŠãããããã®è «çã®æ²»çã«çšãã
è©Šã¿ããªãããŠããããæãŸããæè «çå¹æã¯åŸ
ãããŠããªãã ããã«ãè «çæäœã«æè «çå€ãååŠçã«çµåã
ããŠæ°èŠãªååç©ã補é ããããã«ããæè «çå¹
æãæåŸ ããäºãææ¡ãããŠããããïŒäŸãã°è±
åœç¹èš±ç¬¬1446536ïŒãäžèšååŠåå¿ã®æ¡ä»¶ãéé ·ã
ããããã«ååãªçµæã¯åŸãããŠããªãããŸãã
ãããã®å®éšã§çšããããæäœã¯å ç«ã°ãããªã³
ç»åãŸã§ã®ç²Ÿè£œããè¡ãããŠããªãã®ã§ãäžè¬ã®
å ç«ã°ãããªã³ãå«æããŠããŠãçã®æå³ã§ã¯çŽ
ç²ãªè «çæäœãšã¯èªãé£ãããã®æ§ãªå Žåã«ã¯ã
äžè¬ã®å ç«ã°ãããªã³ã®çºã«æäžãããåŽã«æ£åžž
çµç¹ã®é害ãå šèº«çæ£ãŸãã¯ç¡¬çŽãªã©ã®ã¢ããã©
ãã·ãŒã·ãšãã¯ã®çããäºãå€ããå³ã¡å ç«ã°ã
ããªã³ç»åãæŽã«ç²Ÿè£œããŠããããäžè¬å ç«ã°ã
ããªã³ãæŽã«é€ãå¿ èŠãããã æ¬çºæã¯ãåç©ã«æ¥çš®ããè «çã®æåã«å¯Ÿãã
æäœãå«ãæè¡æž ãæ¡åãããã®äžã®å ç«ã°ãã
ãªã³ç»åãååããæŽã«ã¢ãã€ããã€âã¯ããã
ã°ã©ãã€ãŒã«ãã粟補ãè¡ãããšã«ãã€ãŠããã
çŽç²ãªè «çæäœãå ãåé¢ãããããæè «çå€ãš
çµåãããã®ã§ããããã®éã«ãæäœããã³æè «
çå€ã®äž¡è ã«å æ¥ååšããŠããã¢ããåºåã¯ã«ã«
ããã·ã«åºãç©åãªæ¡ä»¶äžã«åå¿ããããŠãæäœ
ãšæè «çå€ãšãã¢ããçµåã§çµåããããæŽã«ã
æè «çå€ã«çµåå€ãåå¿ãããŠã¢ããåºåã¯ã«ã«
ããã·ã«åºãå°å ¥åŸæäœã«ã¢ããçµåã«ããçµå
ãããŠããããæ¬çºæã«ãããšãæäœã®åè «çæ§
ãšæè «çæ§ãªãã³ã«æè «çå€ã®æè «çæ§ã¯å€±ãã
ãããšãªãäžèšååç©ã«ãã®ãŸãŸä¿ãããŠããã®
ã§ãæ¬çºæã«ããååç©ïŒä»¥äžæ¬ååç©ãšããïŒ
ã¯æäžããããšå¹çããç®çãšããè «çéšäœã«å°
éããæè «çå¹æãçºæ®ãããåŸã€ãŠæ¬ååç©ã
ãã®æåãšããŠå«æããæè «çå€ã®ééãåºæºãš
ããŠèãããªãã°ãåäžã®æè «çå€ãã®ãã®ã®æ
äžéã®1/10ã1/20ã«çžåœããééã®æè «çå€ãæ
åãšããŠå«æããæ¬ååç©ã®æäžã«ãã€ãŠåçšåºŠ
ã®è «çå¢æ®æå¶ãåŸããããã€æåãšããŠå«æã
ãæè «çå€ã«ããå¯äœçšã¯ãåäžã®æè «çå€ãã®
ãã®ã®æäžã®å Žåã®1/10ã1/20ã«ãããªããšæåŸ
ããããããã¯æ¬ååç©ã®æåããããã®å¥œãŸã
ãæ§è³ªã®è€åå¹æãšäºãããšãã§ããã æ¬ååç©ã®è£œé ã«çšããæè «çå€ã¯äžè¬ã®æè «
çå€ã®äžããéžã°ããã®ã§ããããçš®ã ã®ç¹ãã
èŠãŠæçç©è³ªã奜ãŸãããç¹ã«æäœãšã®ã¢ããçµ
åãæåŸ ããçç±ããããããå¯èœãšããã¢ãã
åºããã³ãŸãã¯ã«ã«ããã·ã«åºãæãããã€ãã
ã€ã·ã³ïŒ£ãå¡©é žãããœã«ãã·ã³ããã¬ãªãã€ã·
ã³ãããŠãã«ãã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³
ã¶ã«ã³ãã€ã·ã³ãªã©ã奜ãŸããã ãŸããæ¬ååç©ã®åæã®ïŒã€ã§ããæäœãšããŠ
ã¯ãè «çã®æäœãçšããããè «çãšããŠã¯ã¶ã«ã³
ãŒã180ãäœè€èºçãâ1210çœè¡ç ãâ388çœ
è¡ç ããšãŒãªããçãåç°èè «ãæ¥æ§ãªã³ãæ§çœ
è¡ç ã骚é«çããã³ãã®ä»ã®äººçããéžã°ããè «
çãããããããæ¬çºæã§çšããæäœã®è£œé ã¯æ¥
æ¬å ç«åŠäŒç·äŒèšé²ç¬¬ïŒå·»ã198é ïŒ1976幎ïŒèš
èŒã®æ¹æ³ã«ããåã¯DauphinãM.J.ãJ.
Immunol.113ã948ïŒ1974ïŒèšèŒã®æ¹æ³ã«æºããŠ
è¡ããåè ã¯ããã€ã³ãïŒFreundïŒã®ã³ã³ããª
ãŒãã¢ãžãŠãã³ãïŒComplete AjuvantïŒãçš
ããå ãè «ç现èãåç©ã«ç®äžæ³šå°ããããšã«ã
ã€ãŠããããããå ç«ããæŽã«ç¶ããŠè «ç现èã
éèå ã«æ³šå°ããããšã«ããè¿œå å ç«ããŠããã
ããæäœãåŸãæ¹æ³ã§ãããåŸè ã¯è «ç现èãå
ç©ã®è ¹è å ã«ïŒãïŒååèŠæäžããŠãåç©ãå ç«
ããŠããããæäœãåŸãæ¹æ³ã§ãããæ¬çºæã§çš
ããæäœã¯åçš®æäœãç°çš®æäœã®ãããã§ããã
ããåçš®æäœã奜ãŸãããããããŠåŸãæäœã¯ã
ã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒã«ãããã«ã©ã
ã®å å¡«å€ã«æ²»çç®çã®è «çæåãå ãããã ã·ã¢
ã³ãçšããŠçµåããããŠãããŠããããã«ã©ã ã«
å å¡«ããã«ã©ã ã«å ç«ã°ãããªã³ç»åè¿ç²Ÿè£œãã
æäœã®æº¶æ¶²ãæµå ¥ãããããããŠã«ã©ã äžã§æå
ãšæäœãšãçµåãããåŸã«ç¹æ®ãªæº¶å€ãã«ã©ã ã«
æµå ¥ããŠãæåã»æäœçµåã解ãããŠãæäœã®ã¿
ã溶åºãããæŽã«ãããéæããŠç²Ÿè£œæäœæ°Žæº¶æ¶²
ãåŸããããªãã¡ãããããŠåŸãããæäœã¯åŸæ¥
ã®å ç«ã°ãããªã³ç»åãããæŽã«çŽåºŠã®é«ãæè «
çå ç«ã°ãããªã³ã§ãããäžè¬ã«æäœã®ç²Ÿè£œã«
ã¯ãç¡«å®å¡©æãšDEAEã»ã«ããŒã¹ã«ã©ã ã«ããã€
ãªã³äº€æã¯ãããã°ã©ãã€ãŒã䜿ã€ãŠãæè¡æž ã
ãåç»ãåŸãæ¹æ³ããã°ãã°çšãããããæ¬çºæ
ã§ã¯ãããã«å ããŠãã¢ãã€ããã€ã¯ãããã°ã©
ãã€ãŒãçšããŠè «ç现èã«å¯Ÿããç¹ç°çæäœã®ã¿
ãéžæçã«åŸãçºã®ç¹ç°ç粟補æäœãè¡ãªã€ãã ã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒã¯ãé µçŽ ãšåº
質ãæäœãšæåãªã©ã®ãããªçäœç©è³ªçžäºéã«å
ãç¹ç°ç芪ååãå©çšããäžæ¹ã®çäœç©è³ªã䜿ã€
ãŠä»æ¹ãéžæçã«åé¢ãããšããåçã«ããšã¥ã
ãã®ã§ããã æ¬çºæã§çšããããã¢ãã€ããã€ã¯ãããã°ã©
ãã€ãŒã«ã¯ã(1)è «ç现èããæœåºããæåãã»ã
ã¢ããŒã¹ïŒShephroseRïŒã®ããšãæ äœã«ïŒãã
ã ã·ã¢ã³ãçšããŠïŒå ±æçµåããããããã«ã©ã
ã«å å¡«ããæäœæº¶æ¶²ãéããŠãæäœãæåã«çµå
ãããæŽã«ååéã®æº¶åªãæµããŠçµåããªãã€ã
æäœãæŽãå»ã€ãåŸãPHã®ããäœãç·©è¡æº¶æ¶²ãæµ
ãå ¥ããŠãæäœã»æåã®å Žåã解ããŠãåé¢ãã
æäœã溶åºãããæ¹æ³ã(2)ã«ã©ã ãçšãããæå
ãçµåãããæ äœãšæäœæº¶æ¶²ãæ··åããŠæäœãæ
åã«çµåãããæ äœç²åãæŽæµããŠçµåããªãã€
ãæäœãé€ããåŸãæäœã溶é¢ãããæ¹æ³ããã
ã³(3)äžèšã§æåãçµåãããæ äœã®ä»£ãã«ãè «ç
现èèªèº«ãçšããæ¹æ³ãå«ããå®æœäŸã§çšããæ¹
æ³ã¯(1)ãš(3)ã§ããã åŸã€ãŠãã¢ãã€ããã€ã¯ãããã°ã©ãã€ã«ãã€
ãŠç²Ÿè£œãããæäœã¯åŸæ¥ã®å ç«ã°ãããªã³ç»åã
ããé¥ã«çŽåºŠã®é«ãæè «çå ç«ã°ãããªã³å³ã¡æ
è «çæäœã§ããã ããããŠåŸãããæäœãæè «çå€ã«çµåããã
ã«ã¯ãã¢ããåºåã¯ã«ã«ããã·ã«åºãæããæè «
çå€ãããã¯ã¢ããåºåã¯ã«ã«ããã·ã«åºãå°å ¥
ããæè «çå€ãšæäœãæ°Žæ§æº¶åªäžã«æº¶è§£ãããã
氎溶æ§ã®ã«ã«ããžã€ãã觊åªãäŸãã°ïŒâãšãã«
âïŒâïŒïŒâãžã¡ãã«ã¢ãããããã«ïŒâã«ã«ããž
ã€ãããïŒâã·ã¯ãããã·ã«âïŒâïŒïŒâã¢ã«ã
ãªããšãã«ïŒã«ã«ããžã€ããåã¯ãžã·ã¯ãããã·
ã«ã«ã«ããžã€ãããªã©ãå ããŠãïŒã50âã奜ãŸ
ããã¯10ã40âã§ã10åãïŒæéã奜ãŸããã¯30
åãïŒæéåå¿ãããé ¢é žâé ¢é žãããªãŠã ç·©è¡
溶液ãªã©ã®æ·»å ã§åå¿ãåæ¢ãããã次ãã§ãã®
åå¿æ¶²äžã®éå°ãªæè «çå€ã觊åªããã³åæ¢å€ã®
æåãªãã³ã«å¡©é¡ãé€ãçºã«ãéæãå¡©æãã²ã«
éããã³éå€éã®äœããã®æäœãè¡ããåã¯
ãããã®æäœãçµåããæäœãè¡ãããŸããäžè¿°
ããæè «çå€ã«ã¢ããåºåã¯ã«ã«ããã·ã«åºãå°
å ¥ããã«ã¯ãæè «çå€ãã®ãŸãŸãæãããã®ãã
ãªãŠã å¡©ãã«ãªãŠã å¡©åã¯ã¢ã«ãããŠã å¡©ã«ã äžè¬åŒ ïŒCH2ïŒnCOOHã ïŒåŒäžïŒžã¯Bråã¯Clãè¡šãããïœã¯ïŒä¹è³ïŒã®æŽ
æ°ãè¡šããïŒ ãããã¯ãäžè¬åŒ HClã»NH2ïŒCH2ïŒnCOX ïŒåŒäžïŒžã¯Bråã¯Clãè¡šãããïœã¯ïŒä¹è³ïŒã®æŽ
æ°ãè¡šããïŒ ã§ç€ºãããååç©ã奜ãŸããã¯ã¢ãã¯ãã«é ¢é ž
ããæ°Žæ§æº¶åªäŸãã°æ°Žãã¡ã¿ããŒã«ããšã¿ããŒ
ã«ããžãªããµã³ãããã¯ãžã¡ãã«ã¹ã«ããã·ã
ïŒDMSOïŒäžã§ïŒã50âã奜ãŸããã¯10ã40âã§
10åã72æéåå¿ããããšããããã®åå¿çæç©
ããæ°Žãã¢ã«ã³ãŒã«ãã¯ãããã«ã ããžãªããµã³
ã®ããšã溶åªãçšããŠåçµæ¶ããããšãã¢ããåº
åã¯ã«ã«ããã·ã«åºãå°å ¥ãããæè «çå€èªå°äœ
ãåŸãããã æ¬ååç©ã¯æäœïŒååã«å¯ŸããŠæè «çå€ã®ïŒã
ïŒååãçµåããŠãªããã®ã§ããã æ¬ååç©ã®åºä¹³åç©ã«å¯Ÿããæ¥æ§æ¯æ§ãããŠã¹
ã«300mgïŒKgã®æäžéã§éè泚å°ããŠèª¿ã¹ããã
ïŒé±éã®èŠ³å¯ã§ã¯æ»äº¡ãèªããããªãã€ãã äžè¿°ã®ããšããæ¬ååç©ã¯æ¯æ§ãäœãåçš®ã®äºº
çãäŸãã°æ ¢æ§ãªã³ãæ§çœè¡ç ãæªæ§ãªã³ãè «ã
骚é«çãåµå·£çãä¹³çãèè «ãçœè¡ç ãçè «ãªã©
ã«å¯Ÿãæå¹ãªå¶çæ§ãæããã æ¬ååç©ãæè «çå€ãšããŠçšããå Žåã®è£œå€å
ããã³æäžæ¹æ³ã¯åŸæ¥ã®æè «çå€ã«é¢ããå ¬ç¥ã®
ææ³ãé©çšãåŸããããªãã¡ãæ¬ååç©ã®æäžã«
ã¯çµå£ã泚å°åã¯çŽè žæäžãé©çšãããæäžåœ¢æ
ãšããŠã¯ç²æ«ãé¡ç²ãé å€ã泚å°å€ã座è¬ãªã©ã®
圢æ ãæ¡ãåŸãããªããæäžã¯æ³šå°åœ¢æ ãç¹ã«å¥œ
ãŸããããã®è£œå€åã«ã¯æ°Žæº¶æ§æº¶å€ãéæ°Žæ§æº¶
å€ãç匵åå€ãç¡çåå€ã溶解è£å©å€ãå®å®å€ã
é²è å€ãæžæ¿åå€ãç·©è¡å€ãä¹³åå€çãé©å®äœ¿çš
ãåŸããäŸãã°ãçççé£å¡©æ°Žãæ» èæ°Žããªã³ã²
ã«æ¶²ãªã©ãäžè¬çã«äœ¿çšãããã ããã«æ¬ååç©ã®æ³šå°æ¶²ã®è£œå€åãäŸç€ºãã
ãšãæ¬ååç©10mgãšãã³ãããŒã«50mgãèžçæ°Žã«
溶解ããŠ1210mlãšãªãããã®ãåžžæ³ã«ããé€èã
ãã®ã¡ã泚å°çšå°ç¶ã«å泚ãããåã¯ãã®ãŸãŸå
çµä¹Ÿç¥ããæäžã«éããŠçççé£å¡©æ°Žã§çšéããŠ
泚å°æ¶²ãšããã 補å€åã«éããŠã¯æ¬ååç©ã¯è£œå€äžã«äžè¬ã«
0.01ã90ïŒ å¥œãŸããã¯0.1ã60ïŒ å«æãåŸãã ãŸããæ¬ååç©ã®æäžéã¯äž»ãšããŠçç¶ã«ãã
ãæ人ïŒäººïŒæ¥åœã0.01ã3000mg奜ãŸããã¯0.1
ã500mgã§ããã 以äžæ¬çºæãå®æœäŸã«ãã€ãŠããã«è©³çŽ°ã«èª¬æ
ããã å®æœäŸ ïŒ ïŒâïŒïŒã¢ãã€ããã€ã¯ãããã°ã©ãã€(3)ãå©çš
ããæäœã®èª¿è£œãšç²Ÿè£œ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ããè ¹æ°Žåã¶ã«
ã³ãŒãâ180现èãçççé£å¡©æ°Žã«æžæ¿ãããŠ
ãã€ããã€ã·ã³ïŒ£ïŒ50ÎŒïœïŒmlïŒãå ããŠ30å
é37âã§åŠçããåŸãé å¿åé¢ã«ãã€ãŠäžæž ã
é€ãã现èã0.85ïŒ ã®ççé£å¡©æ°Žã§ïŒåæŽæ»ã
ããããããŠå¢æ®èœã倱ã€ãã¶ã«ã³ãŒã180è «
ç现èã«ããã€ã³ãïŒFreundïŒã®ã³ã³ããªãŒ
ãã¢ãžãŠãã³ãïŒComplete AjuvantïŒïŒFCA
ãšç¥ãïŒãæ··åããäœé2.9Kgã®ãŠãµã®è¶³è¹ ã®
ç®äžã«ïŒå¹åœã现è108åã®å²åã§æ³šå°ããïŒ
é±éåŸã«åæ§ãªæ¹æ³ã§æ³šå°ããŠãŠãµã®ãå ç«
ããæŽã«ïŒé±éåŸåäžã®çŽ°è108åããã®ãŠãµ
ã®ã®éèã«æ³šå°ãããïŒé±éçµéåŸã«é åèã«
ã«ããŠãŒã¬ãæ¿å ¥ããŠå šè¡ãæ¡åãããããã
æè¡æž ãåé¢ããŠäžèšã®ç²Ÿè£œãè¡ã€ããå³ã¡ã
100mlã®æè¡æž ã«ç¡«é žã¢ã³ã¢ããŠã ã飜åéã®
20ã30ïŒ æ·»å ããŠçããå¡©æç»åãæ¡åããŠã
ããã20mlã®æ°Žã«å溶解ãããã®æº¶æ¶²ãPH7.0
ã®10ïœïŒçé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒPBSãšç¥ãïŒ
ã«å¯ŸããŠïŒâã72æééæããŠè±å¡©ããïŒãã®
éã24æéæ¯ã«éæå€æ¶²ã®äº€æãè¡ã€ãïŒãé
æå 液ã«ãé£å¡©æ°Žã§ïŒåæŽæµããæ£åžžãªICRã
ãŠã¹ã®è¡çãçéæ··åããïŒâã§30åæŸçœ®ããŠ
åžåãè¡ããããåŸãé å¿åé¢ããŠäžæž ãåŸ
ãããã®åžåæäœãæŽã«ïŒåè¡ã€ãŠãå šéšã§ïŒ
åã®åžåæäœãå ããããããŠåŸãããæäœã
粟補åæäœãšäºãïŒé称IgGïŒã次ãã§äžèšã®
æ¹æ³ã§æŽã«ç²Ÿè£œãè¡ã€ããå³ã¡äžèšåžåã®æžã
ã äžæž ã«ãã¶ã«ã³ãŒãâ180现èãçéæ··å
ããïŒâã«30åæŸçœ®ããŠã¶ã«ã³ãŒãâ180ã«å¯Ÿ
ããæäœãã¶ã«ã³ãŒãâ180è «ç现èã«çµåã
ããåŸãé å¿åé¢ããŠäžæž ãé€ããæ²æŸ±ã«PH
3.0ã®ã°ãªã·ã³âå¡©é žç·©è¡æ¶²ãå ããŠãæäœã
éé¢ãããããã®æ··åç©ãé å¿åé¢ããŠãæäœ
ãå«ãäžæž ãæ¡åãããäžæž ã®PHã0.1Mèæ§
ãœãŒã氎溶液ã§äžæ§è¿ãã«èª¿æŽããåŸãPBSã«
察ããŠïŒâã§24æééæãè¡ã€ãïŒïŒæéæ¯ã«
éæå€æ¶²ã亀æããïŒããããŠè¡ããããã®ã
ãŠãµã®ã®æã¶ã«ã³ãŒãâ180è «çå ç«æäœã®æ°Ž
溶液ã§ããã ïŒâïŒïŒè «ç现èããã³æ£åžžçŽ°èã«å¯Ÿããé害æ§
è©ŠéšïŒãã®ïŒïŒ äžèšã§åŸããŠãµã®ã®æã¶ã«ã³ãŒãâ180è «ç
å ç«æäœã«ã€ããŠè£äœïŒã¢ã«ã¢ããã®è¡æž ïŒå
åšäžã®çŽ°èé害詊éšãè¡ã€ããå³ã¡äžèšæäœæ°Ž
溶液åã¯ããã10ã100ããã³1000åã«çšéã
ããã®ãšãã¶ã«ã³ãŒãâ180è «ç现èæµ®é液æ
ã¯æ£åžžICRããŠã¹èŸçŽ°èæµ®é液ïŒäœããã€ãŒã°
ã«ïŒEagleïŒã®Minimum Essential Medium
ïŒä»¥äžMEMãšç¥ãïŒã溶åªãšããŠçšãã现èæ¿
床ã¯ïŒÃ106åïŒmlãšããïŒãšã100ÎŒå®æ··å
ãã宀枩ã§15åæŸçœ®ããŠæäœãããããã®çŽ°è
ã«çµåããããããã®åŸã¢ã«ã¢ããã®è¡æž ãã€
ãŒã°ã«ã®MEMã§ïŒåã«çšéãïŒãããè£äœãš
ããïŒãã®100ÎŒããäžèšã®æ··å液ã«å ãã
37âã§30åå¹é€ããé å¿åé¢ããŠãæ²æŸ±ãã€ãŒ
ã°ã«ã®MEMã§ïŒåæŽæ»ããããã«ããªãã³ã
ã«ãŒæ¶²ãå ããŠãé¡åŸ®é¡äžã§äžèšããããã®çŽ°
èã®æ»æ» ã®çšåºŠã芳å¯ããã ãã®çµæã¯äžèšã®ç¬¬ïŒè¡šã«ç€ºãããšãã现è
ã®æ»æ» çšåºŠïŒçŽ°èé害掻æ§ïŒãïŒãïŒïŒãïŒïŒïŒ
ã®ïŒæ®µéã«åããŠè¡šç€ºããïŒæ»æ» ãªãã¯âã§ç€º
ãïŒãšæè¡æž ãäžèšã®æ¹æ³ã§ç²Ÿè£œããåŸã«æäœ
ãåãåºãããã®ã¯ãæè¡æž ã粟補ããããšãª
ãæäœãåãåºãããã®ã«ããã¹ãŠã¶ã«ã³ãŒã
â180现èã«å¯Ÿããæ¯æ§ã¯ããŸã倧ããç°ãªã
ãªãããæ£åžžã®ICRããŠã¹èŸçŽ°èã«å¯Ÿããæ¯æ§
ã¯æ¥µããŠäœããããã殺ãããšã¯ãªãã€ããå³
ã¡æè¡æž ã®ç²Ÿè£œã¯ç®çã«ããªã€ãŠããããšãã
ã瀺ãããã
ãŠãæŽã«è©³ããã¯è «çæåã«å¯Ÿããæäœã«æè «ç
å€ãç¹ã«ææ§ç©è³ªç³»æè «çå€ãäŸãã°ãã€ããã€
ã·ã³ïŒ£ãå¡©é žãããœã«ãã·ã³ããã¬ãªãã€ã·ã³ã
ããŠãã«ãã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³ã¶ã«
ã³ãã€ã·ã³ã®ããšãå°ããšãïŒåã®ã¢ããåºãã
ãã¯ã«ã«ããã·ã«åºãæããæè «çç©è³ªåã¯è©²æ
è «çç©è³ªã«çµåå€ãçµåãããç©è³ªãã¢ããåºå
ã¯ã«ã«ããã·ã«åºãä»ããŠçµåãããŠãªãååç©
ãæå¹æåãšããŠå«æããæè «çå€ã«é¢ãããã®
ã§ããã æ¬çºæã¯ãäžèšã®çŽ°èæ¯æ§ã®é«ãæè «çå€ãã
極ããŠç·©åãªæ¡ä»¶äžã§ã¢ãã€ãã€ãã€âã¯ããã
ã°ã©ãã€ãŒã«ãã粟補ãããè «çæåã«å¯Ÿããæ
äœã«ã¢ããçµåïŒâNHCOâïŒã«ãã€ãŠçµåãã
ãæ°èŠãªååç©ã«åºãæè «çå€ã§ãã€ãŠãæè «ç
å¹æã«ããããªãã现èæ¯æ§ã¯ãåæã®ïŒã€ã§ã
ãæè «çå€ã«ããã¹ãŠæ Œæ®µã«äœãæè «çå€ãæäŸ
ããããšãç®çãšããã è¿å¹Žçš®ã ã®æè «çå€ãåºã䜿çšãããŠãæãçš
床ã®å¹æããããŠããããããã®äžã«ã¯åèšã®ã
ã€ããã€ã·ã³ïŒ£ãå¡©é žãããœã«ãã·ã³ããã¬ãªã
ã€ã·ã³ãããŠãã«ãã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ã
ã¶ã«ã³ãã€ã·ã³çããããããããèªèº«ã¯äœãã
é«ã现èæ¯æ§ãæããŠããŠãæäžããéã«çœè¡ç
æžå°ãè±æ¯ãèè žé害çã®å¯äœçšãåããããšã
ç¥ãããŠããããã®çºã«ãããè¬å€ã®äœ¿çšã«é床
ã®ããã®ãå®æ ã§ããã äžæ¹ãããçš®ã®è «çã®æåã«å¯Ÿããæäœã補é
ãŸãã¯åé¢ããŠãããããã®è «çã®æ²»çã«çšãã
è©Šã¿ããªãããŠããããæãŸããæè «çå¹æã¯åŸ
ãããŠããªãã ããã«ãè «çæäœã«æè «çå€ãååŠçã«çµåã
ããŠæ°èŠãªååç©ã補é ããããã«ããæè «çå¹
æãæåŸ ããäºãææ¡ãããŠããããïŒäŸãã°è±
åœç¹èš±ç¬¬1446536ïŒãäžèšååŠåå¿ã®æ¡ä»¶ãéé ·ã
ããããã«ååãªçµæã¯åŸãããŠããªãããŸãã
ãããã®å®éšã§çšããããæäœã¯å ç«ã°ãããªã³
ç»åãŸã§ã®ç²Ÿè£œããè¡ãããŠããªãã®ã§ãäžè¬ã®
å ç«ã°ãããªã³ãå«æããŠããŠãçã®æå³ã§ã¯çŽ
ç²ãªè «çæäœãšã¯èªãé£ãããã®æ§ãªå Žåã«ã¯ã
äžè¬ã®å ç«ã°ãããªã³ã®çºã«æäžãããåŽã«æ£åžž
çµç¹ã®é害ãå šèº«çæ£ãŸãã¯ç¡¬çŽãªã©ã®ã¢ããã©
ãã·ãŒã·ãšãã¯ã®çããäºãå€ããå³ã¡å ç«ã°ã
ããªã³ç»åãæŽã«ç²Ÿè£œããŠããããäžè¬å ç«ã°ã
ããªã³ãæŽã«é€ãå¿ èŠãããã æ¬çºæã¯ãåç©ã«æ¥çš®ããè «çã®æåã«å¯Ÿãã
æäœãå«ãæè¡æž ãæ¡åãããã®äžã®å ç«ã°ãã
ãªã³ç»åãååããæŽã«ã¢ãã€ããã€âã¯ããã
ã°ã©ãã€ãŒã«ãã粟補ãè¡ãããšã«ãã€ãŠããã
çŽç²ãªè «çæäœãå ãåé¢ãããããæè «çå€ãš
çµåãããã®ã§ããããã®éã«ãæäœããã³æè «
çå€ã®äž¡è ã«å æ¥ååšããŠããã¢ããåºåã¯ã«ã«
ããã·ã«åºãç©åãªæ¡ä»¶äžã«åå¿ããããŠãæäœ
ãšæè «çå€ãšãã¢ããçµåã§çµåããããæŽã«ã
æè «çå€ã«çµåå€ãåå¿ãããŠã¢ããåºåã¯ã«ã«
ããã·ã«åºãå°å ¥åŸæäœã«ã¢ããçµåã«ããçµå
ãããŠããããæ¬çºæã«ãããšãæäœã®åè «çæ§
ãšæè «çæ§ãªãã³ã«æè «çå€ã®æè «çæ§ã¯å€±ãã
ãããšãªãäžèšååç©ã«ãã®ãŸãŸä¿ãããŠããã®
ã§ãæ¬çºæã«ããååç©ïŒä»¥äžæ¬ååç©ãšããïŒ
ã¯æäžããããšå¹çããç®çãšããè «çéšäœã«å°
éããæè «çå¹æãçºæ®ãããåŸã€ãŠæ¬ååç©ã
ãã®æåãšããŠå«æããæè «çå€ã®ééãåºæºãš
ããŠèãããªãã°ãåäžã®æè «çå€ãã®ãã®ã®æ
äžéã®1/10ã1/20ã«çžåœããééã®æè «çå€ãæ
åãšããŠå«æããæ¬ååç©ã®æäžã«ãã€ãŠåçšåºŠ
ã®è «çå¢æ®æå¶ãåŸããããã€æåãšããŠå«æã
ãæè «çå€ã«ããå¯äœçšã¯ãåäžã®æè «çå€ãã®
ãã®ã®æäžã®å Žåã®1/10ã1/20ã«ãããªããšæåŸ
ããããããã¯æ¬ååç©ã®æåããããã®å¥œãŸã
ãæ§è³ªã®è€åå¹æãšäºãããšãã§ããã æ¬ååç©ã®è£œé ã«çšããæè «çå€ã¯äžè¬ã®æè «
çå€ã®äžããéžã°ããã®ã§ããããçš®ã ã®ç¹ãã
èŠãŠæçç©è³ªã奜ãŸãããç¹ã«æäœãšã®ã¢ããçµ
åãæåŸ ããçç±ããããããå¯èœãšããã¢ãã
åºããã³ãŸãã¯ã«ã«ããã·ã«åºãæãããã€ãã
ã€ã·ã³ïŒ£ãå¡©é žãããœã«ãã·ã³ããã¬ãªãã€ã·
ã³ãããŠãã«ãã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³
ã¶ã«ã³ãã€ã·ã³ãªã©ã奜ãŸããã ãŸããæ¬ååç©ã®åæã®ïŒã€ã§ããæäœãšããŠ
ã¯ãè «çã®æäœãçšããããè «çãšããŠã¯ã¶ã«ã³
ãŒã180ãäœè€èºçãâ1210çœè¡ç ãâ388çœ
è¡ç ããšãŒãªããçãåç°èè «ãæ¥æ§ãªã³ãæ§çœ
è¡ç ã骚é«çããã³ãã®ä»ã®äººçããéžã°ããè «
çãããããããæ¬çºæã§çšããæäœã®è£œé ã¯æ¥
æ¬å ç«åŠäŒç·äŒèšé²ç¬¬ïŒå·»ã198é ïŒ1976幎ïŒèš
èŒã®æ¹æ³ã«ããåã¯DauphinãM.J.ãJ.
Immunol.113ã948ïŒ1974ïŒèšèŒã®æ¹æ³ã«æºããŠ
è¡ããåè ã¯ããã€ã³ãïŒFreundïŒã®ã³ã³ããª
ãŒãã¢ãžãŠãã³ãïŒComplete AjuvantïŒãçš
ããå ãè «ç现èãåç©ã«ç®äžæ³šå°ããããšã«ã
ã€ãŠããããããå ç«ããæŽã«ç¶ããŠè «ç现èã
éèå ã«æ³šå°ããããšã«ããè¿œå å ç«ããŠããã
ããæäœãåŸãæ¹æ³ã§ãããåŸè ã¯è «ç现èãå
ç©ã®è ¹è å ã«ïŒãïŒååèŠæäžããŠãåç©ãå ç«
ããŠããããæäœãåŸãæ¹æ³ã§ãããæ¬çºæã§çš
ããæäœã¯åçš®æäœãç°çš®æäœã®ãããã§ããã
ããåçš®æäœã奜ãŸãããããããŠåŸãæäœã¯ã
ã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒã«ãããã«ã©ã
ã®å å¡«å€ã«æ²»çç®çã®è «çæåãå ãããã ã·ã¢
ã³ãçšããŠçµåããããŠãããŠããããã«ã©ã ã«
å å¡«ããã«ã©ã ã«å ç«ã°ãããªã³ç»åè¿ç²Ÿè£œãã
æäœã®æº¶æ¶²ãæµå ¥ãããããããŠã«ã©ã äžã§æå
ãšæäœãšãçµåãããåŸã«ç¹æ®ãªæº¶å€ãã«ã©ã ã«
æµå ¥ããŠãæåã»æäœçµåã解ãããŠãæäœã®ã¿
ã溶åºãããæŽã«ãããéæããŠç²Ÿè£œæäœæ°Žæº¶æ¶²
ãåŸããããªãã¡ãããããŠåŸãããæäœã¯åŸæ¥
ã®å ç«ã°ãããªã³ç»åãããæŽã«çŽåºŠã®é«ãæè «
çå ç«ã°ãããªã³ã§ãããäžè¬ã«æäœã®ç²Ÿè£œã«
ã¯ãç¡«å®å¡©æãšDEAEã»ã«ããŒã¹ã«ã©ã ã«ããã€
ãªã³äº€æã¯ãããã°ã©ãã€ãŒã䜿ã€ãŠãæè¡æž ã
ãåç»ãåŸãæ¹æ³ããã°ãã°çšãããããæ¬çºæ
ã§ã¯ãããã«å ããŠãã¢ãã€ããã€ã¯ãããã°ã©
ãã€ãŒãçšããŠè «ç现èã«å¯Ÿããç¹ç°çæäœã®ã¿
ãéžæçã«åŸãçºã®ç¹ç°ç粟補æäœãè¡ãªã€ãã ã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒã¯ãé µçŽ ãšåº
質ãæäœãšæåãªã©ã®ãããªçäœç©è³ªçžäºéã«å
ãç¹ç°ç芪ååãå©çšããäžæ¹ã®çäœç©è³ªã䜿ã€
ãŠä»æ¹ãéžæçã«åé¢ãããšããåçã«ããšã¥ã
ãã®ã§ããã æ¬çºæã§çšããããã¢ãã€ããã€ã¯ãããã°ã©
ãã€ãŒã«ã¯ã(1)è «ç现èããæœåºããæåãã»ã
ã¢ããŒã¹ïŒShephroseRïŒã®ããšãæ äœã«ïŒãã
ã ã·ã¢ã³ãçšããŠïŒå ±æçµåããããããã«ã©ã
ã«å å¡«ããæäœæº¶æ¶²ãéããŠãæäœãæåã«çµå
ãããæŽã«ååéã®æº¶åªãæµããŠçµåããªãã€ã
æäœãæŽãå»ã€ãåŸãPHã®ããäœãç·©è¡æº¶æ¶²ãæµ
ãå ¥ããŠãæäœã»æåã®å Žåã解ããŠãåé¢ãã
æäœã溶åºãããæ¹æ³ã(2)ã«ã©ã ãçšãããæå
ãçµåãããæ äœãšæäœæº¶æ¶²ãæ··åããŠæäœãæ
åã«çµåãããæ äœç²åãæŽæµããŠçµåããªãã€
ãæäœãé€ããåŸãæäœã溶é¢ãããæ¹æ³ããã
ã³(3)äžèšã§æåãçµåãããæ äœã®ä»£ãã«ãè «ç
现èèªèº«ãçšããæ¹æ³ãå«ããå®æœäŸã§çšããæ¹
æ³ã¯(1)ãš(3)ã§ããã åŸã€ãŠãã¢ãã€ããã€ã¯ãããã°ã©ãã€ã«ãã€
ãŠç²Ÿè£œãããæäœã¯åŸæ¥ã®å ç«ã°ãããªã³ç»åã
ããé¥ã«çŽåºŠã®é«ãæè «çå ç«ã°ãããªã³å³ã¡æ
è «çæäœã§ããã ããããŠåŸãããæäœãæè «çå€ã«çµåããã
ã«ã¯ãã¢ããåºåã¯ã«ã«ããã·ã«åºãæããæè «
çå€ãããã¯ã¢ããåºåã¯ã«ã«ããã·ã«åºãå°å ¥
ããæè «çå€ãšæäœãæ°Žæ§æº¶åªäžã«æº¶è§£ãããã
氎溶æ§ã®ã«ã«ããžã€ãã觊åªãäŸãã°ïŒâãšãã«
âïŒâïŒïŒâãžã¡ãã«ã¢ãããããã«ïŒâã«ã«ããž
ã€ãããïŒâã·ã¯ãããã·ã«âïŒâïŒïŒâã¢ã«ã
ãªããšãã«ïŒã«ã«ããžã€ããåã¯ãžã·ã¯ãããã·
ã«ã«ã«ããžã€ãããªã©ãå ããŠãïŒã50âã奜ãŸ
ããã¯10ã40âã§ã10åãïŒæéã奜ãŸããã¯30
åãïŒæéåå¿ãããé ¢é žâé ¢é žãããªãŠã ç·©è¡
溶液ãªã©ã®æ·»å ã§åå¿ãåæ¢ãããã次ãã§ãã®
åå¿æ¶²äžã®éå°ãªæè «çå€ã觊åªããã³åæ¢å€ã®
æåãªãã³ã«å¡©é¡ãé€ãçºã«ãéæãå¡©æãã²ã«
éããã³éå€éã®äœããã®æäœãè¡ããåã¯
ãããã®æäœãçµåããæäœãè¡ãããŸããäžè¿°
ããæè «çå€ã«ã¢ããåºåã¯ã«ã«ããã·ã«åºãå°
å ¥ããã«ã¯ãæè «çå€ãã®ãŸãŸãæãããã®ãã
ãªãŠã å¡©ãã«ãªãŠã å¡©åã¯ã¢ã«ãããŠã å¡©ã«ã äžè¬åŒ ïŒCH2ïŒnCOOHã ïŒåŒäžïŒžã¯Bråã¯Clãè¡šãããïœã¯ïŒä¹è³ïŒã®æŽ
æ°ãè¡šããïŒ ãããã¯ãäžè¬åŒ HClã»NH2ïŒCH2ïŒnCOX ïŒåŒäžïŒžã¯Bråã¯Clãè¡šãããïœã¯ïŒä¹è³ïŒã®æŽ
æ°ãè¡šããïŒ ã§ç€ºãããååç©ã奜ãŸããã¯ã¢ãã¯ãã«é ¢é ž
ããæ°Žæ§æº¶åªäŸãã°æ°Žãã¡ã¿ããŒã«ããšã¿ããŒ
ã«ããžãªããµã³ãããã¯ãžã¡ãã«ã¹ã«ããã·ã
ïŒDMSOïŒäžã§ïŒã50âã奜ãŸããã¯10ã40âã§
10åã72æéåå¿ããããšããããã®åå¿çæç©
ããæ°Žãã¢ã«ã³ãŒã«ãã¯ãããã«ã ããžãªããµã³
ã®ããšã溶åªãçšããŠåçµæ¶ããããšãã¢ããåº
åã¯ã«ã«ããã·ã«åºãå°å ¥ãããæè «çå€èªå°äœ
ãåŸãããã æ¬ååç©ã¯æäœïŒååã«å¯ŸããŠæè «çå€ã®ïŒã
ïŒååãçµåããŠãªããã®ã§ããã æ¬ååç©ã®åºä¹³åç©ã«å¯Ÿããæ¥æ§æ¯æ§ãããŠã¹
ã«300mgïŒKgã®æäžéã§éè泚å°ããŠèª¿ã¹ããã
ïŒé±éã®èŠ³å¯ã§ã¯æ»äº¡ãèªããããªãã€ãã äžè¿°ã®ããšããæ¬ååç©ã¯æ¯æ§ãäœãåçš®ã®äºº
çãäŸãã°æ ¢æ§ãªã³ãæ§çœè¡ç ãæªæ§ãªã³ãè «ã
骚é«çãåµå·£çãä¹³çãèè «ãçœè¡ç ãçè «ãªã©
ã«å¯Ÿãæå¹ãªå¶çæ§ãæããã æ¬ååç©ãæè «çå€ãšããŠçšããå Žåã®è£œå€å
ããã³æäžæ¹æ³ã¯åŸæ¥ã®æè «çå€ã«é¢ããå ¬ç¥ã®
ææ³ãé©çšãåŸããããªãã¡ãæ¬ååç©ã®æäžã«
ã¯çµå£ã泚å°åã¯çŽè žæäžãé©çšãããæäžåœ¢æ
ãšããŠã¯ç²æ«ãé¡ç²ãé å€ã泚å°å€ã座è¬ãªã©ã®
圢æ ãæ¡ãåŸãããªããæäžã¯æ³šå°åœ¢æ ãç¹ã«å¥œ
ãŸããããã®è£œå€åã«ã¯æ°Žæº¶æ§æº¶å€ãéæ°Žæ§æº¶
å€ãç匵åå€ãç¡çåå€ã溶解è£å©å€ãå®å®å€ã
é²è å€ãæžæ¿åå€ãç·©è¡å€ãä¹³åå€çãé©å®äœ¿çš
ãåŸããäŸãã°ãçççé£å¡©æ°Žãæ» èæ°Žããªã³ã²
ã«æ¶²ãªã©ãäžè¬çã«äœ¿çšãããã ããã«æ¬ååç©ã®æ³šå°æ¶²ã®è£œå€åãäŸç€ºãã
ãšãæ¬ååç©10mgãšãã³ãããŒã«50mgãèžçæ°Žã«
溶解ããŠ1210mlãšãªãããã®ãåžžæ³ã«ããé€èã
ãã®ã¡ã泚å°çšå°ç¶ã«å泚ãããåã¯ãã®ãŸãŸå
çµä¹Ÿç¥ããæäžã«éããŠçççé£å¡©æ°Žã§çšéããŠ
泚å°æ¶²ãšããã 補å€åã«éããŠã¯æ¬ååç©ã¯è£œå€äžã«äžè¬ã«
0.01ã90ïŒ å¥œãŸããã¯0.1ã60ïŒ å«æãåŸãã ãŸããæ¬ååç©ã®æäžéã¯äž»ãšããŠçç¶ã«ãã
ãæ人ïŒäººïŒæ¥åœã0.01ã3000mg奜ãŸããã¯0.1
ã500mgã§ããã 以äžæ¬çºæãå®æœäŸã«ãã€ãŠããã«è©³çŽ°ã«èª¬æ
ããã å®æœäŸ ïŒ ïŒâïŒïŒã¢ãã€ããã€ã¯ãããã°ã©ãã€(3)ãå©çš
ããæäœã®èª¿è£œãšç²Ÿè£œ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ããè ¹æ°Žåã¶ã«
ã³ãŒãâ180现èãçççé£å¡©æ°Žã«æžæ¿ãããŠ
ãã€ããã€ã·ã³ïŒ£ïŒ50ÎŒïœïŒmlïŒãå ããŠ30å
é37âã§åŠçããåŸãé å¿åé¢ã«ãã€ãŠäžæž ã
é€ãã现èã0.85ïŒ ã®ççé£å¡©æ°Žã§ïŒåæŽæ»ã
ããããããŠå¢æ®èœã倱ã€ãã¶ã«ã³ãŒã180è «
ç现èã«ããã€ã³ãïŒFreundïŒã®ã³ã³ããªãŒ
ãã¢ãžãŠãã³ãïŒComplete AjuvantïŒïŒFCA
ãšç¥ãïŒãæ··åããäœé2.9Kgã®ãŠãµã®è¶³è¹ ã®
ç®äžã«ïŒå¹åœã现è108åã®å²åã§æ³šå°ããïŒ
é±éåŸã«åæ§ãªæ¹æ³ã§æ³šå°ããŠãŠãµã®ãå ç«
ããæŽã«ïŒé±éåŸåäžã®çŽ°è108åããã®ãŠãµ
ã®ã®éèã«æ³šå°ãããïŒé±éçµéåŸã«é åèã«
ã«ããŠãŒã¬ãæ¿å ¥ããŠå šè¡ãæ¡åãããããã
æè¡æž ãåé¢ããŠäžèšã®ç²Ÿè£œãè¡ã€ããå³ã¡ã
100mlã®æè¡æž ã«ç¡«é žã¢ã³ã¢ããŠã ã飜åéã®
20ã30ïŒ æ·»å ããŠçããå¡©æç»åãæ¡åããŠã
ããã20mlã®æ°Žã«å溶解ãããã®æº¶æ¶²ãPH7.0
ã®10ïœïŒçé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒPBSãšç¥ãïŒ
ã«å¯ŸããŠïŒâã72æééæããŠè±å¡©ããïŒãã®
éã24æéæ¯ã«éæå€æ¶²ã®äº€æãè¡ã€ãïŒãé
æå 液ã«ãé£å¡©æ°Žã§ïŒåæŽæµããæ£åžžãªICRã
ãŠã¹ã®è¡çãçéæ··åããïŒâã§30åæŸçœ®ããŠ
åžåãè¡ããããåŸãé å¿åé¢ããŠäžæž ãåŸ
ãããã®åžåæäœãæŽã«ïŒåè¡ã€ãŠãå šéšã§ïŒ
åã®åžåæäœãå ããããããŠåŸãããæäœã
粟補åæäœãšäºãïŒé称IgGïŒã次ãã§äžèšã®
æ¹æ³ã§æŽã«ç²Ÿè£œãè¡ã€ããå³ã¡äžèšåžåã®æžã
ã äžæž ã«ãã¶ã«ã³ãŒãâ180现èãçéæ··å
ããïŒâã«30åæŸçœ®ããŠã¶ã«ã³ãŒãâ180ã«å¯Ÿ
ããæäœãã¶ã«ã³ãŒãâ180è «ç现èã«çµåã
ããåŸãé å¿åé¢ããŠäžæž ãé€ããæ²æŸ±ã«PH
3.0ã®ã°ãªã·ã³âå¡©é žç·©è¡æ¶²ãå ããŠãæäœã
éé¢ãããããã®æ··åç©ãé å¿åé¢ããŠãæäœ
ãå«ãäžæž ãæ¡åãããäžæž ã®PHã0.1Mèæ§
ãœãŒã氎溶液ã§äžæ§è¿ãã«èª¿æŽããåŸãPBSã«
察ããŠïŒâã§24æééæãè¡ã€ãïŒïŒæéæ¯ã«
éæå€æ¶²ã亀æããïŒããããŠè¡ããããã®ã
ãŠãµã®ã®æã¶ã«ã³ãŒãâ180è «çå ç«æäœã®æ°Ž
溶液ã§ããã ïŒâïŒïŒè «ç现èããã³æ£åžžçŽ°èã«å¯Ÿããé害æ§
è©ŠéšïŒãã®ïŒïŒ äžèšã§åŸããŠãµã®ã®æã¶ã«ã³ãŒãâ180è «ç
å ç«æäœã«ã€ããŠè£äœïŒã¢ã«ã¢ããã®è¡æž ïŒå
åšäžã®çŽ°èé害詊éšãè¡ã€ããå³ã¡äžèšæäœæ°Ž
溶液åã¯ããã10ã100ããã³1000åã«çšéã
ããã®ãšãã¶ã«ã³ãŒãâ180è «ç现èæµ®é液æ
ã¯æ£åžžICRããŠã¹èŸçŽ°èæµ®é液ïŒäœããã€ãŒã°
ã«ïŒEagleïŒã®Minimum Essential Medium
ïŒä»¥äžMEMãšç¥ãïŒã溶åªãšããŠçšãã现èæ¿
床ã¯ïŒÃ106åïŒmlãšããïŒãšã100ÎŒå®æ··å
ãã宀枩ã§15åæŸçœ®ããŠæäœãããããã®çŽ°è
ã«çµåããããããã®åŸã¢ã«ã¢ããã®è¡æž ãã€
ãŒã°ã«ã®MEMã§ïŒåã«çšéãïŒãããè£äœãš
ããïŒãã®100ÎŒããäžèšã®æ··å液ã«å ãã
37âã§30åå¹é€ããé å¿åé¢ããŠãæ²æŸ±ãã€ãŒ
ã°ã«ã®MEMã§ïŒåæŽæ»ããããã«ããªãã³ã
ã«ãŒæ¶²ãå ããŠãé¡åŸ®é¡äžã§äžèšããããã®çŽ°
èã®æ»æ» ã®çšåºŠã芳å¯ããã ãã®çµæã¯äžèšã®ç¬¬ïŒè¡šã«ç€ºãããšãã现è
ã®æ»æ» çšåºŠïŒçŽ°èé害掻æ§ïŒãïŒãïŒïŒãïŒïŒïŒ
ã®ïŒæ®µéã«åããŠè¡šç€ºããïŒæ»æ» ãªãã¯âã§ç€º
ãïŒãšæè¡æž ãäžèšã®æ¹æ³ã§ç²Ÿè£œããåŸã«æäœ
ãåãåºãããã®ã¯ãæè¡æž ã粟補ããããšãª
ãæäœãåãåºãããã®ã«ããã¹ãŠã¶ã«ã³ãŒã
â180现èã«å¯Ÿããæ¯æ§ã¯ããŸã倧ããç°ãªã
ãªãããæ£åžžã®ICRããŠã¹èŸçŽ°èã«å¯Ÿããæ¯æ§
ã¯æ¥µããŠäœããããã殺ãããšã¯ãªãã€ããå³
ã¡æè¡æž ã®ç²Ÿè£œã¯ç®çã«ããªã€ãŠããããšãã
ã瀺ãããã
ãè¡šã
ãªããããã§æ£åžžçŽ°èã®ä»£è¡šãšããŠçšãã
ICRããŠã¹ã®èŸçŽ°èã¯ãèŸãæåºããåŸããã³
ã»ãããçšããŠã€ãŒã°ã«ã®MEMäžã§ããã现
ãç ãã200meshã®ã¹ãã³ã¬ã¹ç¶²ãééããã
ïŒåMEMã§æŽæ»ããããªã¹âïŒããããã·ã¡ã
ã«ïŒã¢ããã¡ã¿ã³ç·©è¡0.75ïŒ å¡©åã¢ã³ã¢ããŠã
氎溶液ïŒPH7.4ïŒïŒmlãå ããŠè©Šæäžã®èµ€è¡ç
ãç Žå£ãæŽã«ã€ãŒã°ã«ã®MEMã§ïŒåæŽã€ãŠåŸ
ããã®ã§ããã ïŒâïŒïŒã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒ(1)ã«ã
ãæäœã®ç²Ÿè£œ è «çæåãçµåãããã«ã©ã ã䜿çšããã¢ã
ã€ããã€ã¯ãããã°ã©ãã€ãçšããŠäžèšã«ç€ºã
ããšã粟補ãè¡ã€ããå ãæåèªèº«ãäžèšã«ã
ã粟補ãããå³ã¡ICRããŠã¹ãçšããŠç¶ä»£å¹é€
ããè ¹æ°Žåã¶ã«ã³ãŒãâ180è «ç现èãåçµä¹Ÿ
ç¥ãããã®ãã®30ïœã«ïŒïœïŒçé žã«ãªãŠã ç·©è¡
液ã§ç·©è¡ãã3MKCl溶液ïŒPH7.4ïŒãå ããŠæ
åã®æœåºã20æéè¡ããæœåºæ¶²ã65000Gã§10
åéé å¿åé¢ããŠäžæž ãæ¡åããæŽã«ãã®äžæž
ã180000Gã§30åéé å¿åé¢ããŠäžæž ãæ¡å
ããèžçæ°Žã«å¯ŸããŠïŒâã§70æééæããïŒã
ã®é24æéæ¯ã«å€æ¶²ã亀æïŒãéæåŸæŽã«
65000Gã§éæ液ãé å¿åé¢ããŠæ²æŸ±ãé€ãã
äžæž ã«ç¡«é žã¢ã³ã¢ããŠã ãå ããŠ2Mã®æ¿åºŠã«
ããŠããã65000Gã§10åéé å¿åé¢ããŠæ²æŸ±
ãæ¡åããããã®æ²æŸ±ãèžçæ°Žã«å¯ŸããŠ72æé
éæããïŒãã®éã24æéæ¯ã«å€æ¶²ã亀æã
ãïŒã ããããŠåŸãã¶ã«ã³ãŒãâ180è «çæåãçš
ããŠãã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒçšã«ã©
ã ãäžèšã®åŠãäœè£œããã å ããã¢ã¬ããŒã¹ã²ã«ïŒSepharose4BïŒ
Pharmacia Japan Co Ltdã®è£œåïŒãæ°Žã§èšæœ€
ãããŠ20mlãšããããã«ãïŒïœïŒmlã®ããã ã·
ã¢ã³æ°Žæº¶æ¶²20mlãå ããŠãPHã11.0ã«ä¿ã¡ã€ã€
äž¡è ãïŒåéåå¿ãããŠããåå¿ç©ãã¬ã©ã¹
æã§éããæ²æŸ±ãæäžã§æ°·å·ããèžçæ°Žã
次ã«æ°·å·ãã0.5Mçé žæ°ŽçŽ ãããªãŠã 氎溶液
ã§æŽæ»ããåŸãçŽã¡ã«0.1Mçé žæ°ŽçŽ ãããªãŠ
ã 氎溶液ã«æžæ¿ãããããã«äžè¿°ãã粟補æå
氎溶液ãæ·»å ãã宀枩ã§ïŒå€æ¹æããªããåå¿
ãããããçæç©ãã¬ã©ã¹æã§éããå ã
0.1Mçé žæ°ŽçŽ ãããªãŠã 氎溶液ã次ãã§èžç
æ°ŽãæåŸã«çé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH
7.0ïŒã§æŽæ»ããããã®æŽæ»ããåå¿çæç©ã
å åŸ13mmé«ã15cmã®ã¬ã©ã¹ç®¡ã«å å¡«ããŠã¢ãã€
ããã€ã¯ãããã°ã©ãã€çšã«ã©ã ãšããããã®
ã«ã©ã ã«åèšïŒâïŒã®æäœïŒãã ãã¶ã«ã³ãŒã
â180è «ç现èãšã®çµåã«ããæäœã¯çç¥ïŒã§
äœæããæäœæº¶æ¶²ïŒIgGïŒïŒmlãæµå ¥ãã次ã
ã§ïŒïœïŒçé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH
7.0ïŒããã«ã©ã ã®æº¶åºæ¶²ã«èçœãæ€åºãããª
ããªãè¿æµãã次ãã§ã50ïœïŒã°ãªã·ã³âå¡©é ž
ç·©è¡æ°Žæº¶æ¶²ïŒPH4.0ïŒãæ·»å ãã0.5Mé£å¡©æ°Žæº¶
液ãã«ã©ã ã«æµããŠã溶åºããç»åãæ¡åãã
ãããçŽã¡ã«çé žæ°ŽçŽ ãããªãŠã ã§äžæ§ã«ã
ãŠãçé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH7.0ïŒ
ã«å¯ŸããŠ72æééæããïŒ24æéæ¯ã«éæå€æ¶²
ã亀æããïŒãããããŠã«ã©ã ã«ããã¢ãã€ã
ãã€ã¯ãããã°ã©ãã€ãçšããŠç²Ÿè£œããã¶ã«ã³
ãŒãâ180è «çã«å¯Ÿãã粟補æäœæ°Žæº¶æ¶²ãåŸ
ãã ïŒâïŒïŒè «ç现èããã³æ£åžžçŽ°èã«å¯Ÿããé害æ§
è©ŠéšïŒãã®ïŒïŒ äžèšïŒâïŒã§åŸããŠãµã®ã®æã¶ã«ã³ãŒãâ
180è «çå ç«æäœã«ã€ããŠïŒâïŒãšåæ§ãªæ¹æ³
ã§çŽ°èé害æ§è©Šéšãè¡ã€ããçµæã¯äžèšç¬¬ïŒè¡š
ã«ç€ºãã ãªããæ¯èŒãšããŠïŒâïŒã§åŸãæã¶ã«ã³ãŒã
â180è «çæäœã瀺ããã
ICRããŠã¹ã®èŸçŽ°èã¯ãèŸãæåºããåŸããã³
ã»ãããçšããŠã€ãŒã°ã«ã®MEMäžã§ããã现
ãç ãã200meshã®ã¹ãã³ã¬ã¹ç¶²ãééããã
ïŒåMEMã§æŽæ»ããããªã¹âïŒããããã·ã¡ã
ã«ïŒã¢ããã¡ã¿ã³ç·©è¡0.75ïŒ å¡©åã¢ã³ã¢ããŠã
氎溶液ïŒPH7.4ïŒïŒmlãå ããŠè©Šæäžã®èµ€è¡ç
ãç Žå£ãæŽã«ã€ãŒã°ã«ã®MEMã§ïŒåæŽã€ãŠåŸ
ããã®ã§ããã ïŒâïŒïŒã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒ(1)ã«ã
ãæäœã®ç²Ÿè£œ è «çæåãçµåãããã«ã©ã ã䜿çšããã¢ã
ã€ããã€ã¯ãããã°ã©ãã€ãçšããŠäžèšã«ç€ºã
ããšã粟補ãè¡ã€ããå ãæåèªèº«ãäžèšã«ã
ã粟補ãããå³ã¡ICRããŠã¹ãçšããŠç¶ä»£å¹é€
ããè ¹æ°Žåã¶ã«ã³ãŒãâ180è «ç现èãåçµä¹Ÿ
ç¥ãããã®ãã®30ïœã«ïŒïœïŒçé žã«ãªãŠã ç·©è¡
液ã§ç·©è¡ãã3MKCl溶液ïŒPH7.4ïŒãå ããŠæ
åã®æœåºã20æéè¡ããæœåºæ¶²ã65000Gã§10
åéé å¿åé¢ããŠäžæž ãæ¡åããæŽã«ãã®äžæž
ã180000Gã§30åéé å¿åé¢ããŠäžæž ãæ¡å
ããèžçæ°Žã«å¯ŸããŠïŒâã§70æééæããïŒã
ã®é24æéæ¯ã«å€æ¶²ã亀æïŒãéæåŸæŽã«
65000Gã§éæ液ãé å¿åé¢ããŠæ²æŸ±ãé€ãã
äžæž ã«ç¡«é žã¢ã³ã¢ããŠã ãå ããŠ2Mã®æ¿åºŠã«
ããŠããã65000Gã§10åéé å¿åé¢ããŠæ²æŸ±
ãæ¡åããããã®æ²æŸ±ãèžçæ°Žã«å¯ŸããŠ72æé
éæããïŒãã®éã24æéæ¯ã«å€æ¶²ã亀æã
ãïŒã ããããŠåŸãã¶ã«ã³ãŒãâ180è «çæåãçš
ããŠãã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒçšã«ã©
ã ãäžèšã®åŠãäœè£œããã å ããã¢ã¬ããŒã¹ã²ã«ïŒSepharose4BïŒ
Pharmacia Japan Co Ltdã®è£œåïŒãæ°Žã§èšæœ€
ãããŠ20mlãšããããã«ãïŒïœïŒmlã®ããã ã·
ã¢ã³æ°Žæº¶æ¶²20mlãå ããŠãPHã11.0ã«ä¿ã¡ã€ã€
äž¡è ãïŒåéåå¿ãããŠããåå¿ç©ãã¬ã©ã¹
æã§éããæ²æŸ±ãæäžã§æ°·å·ããèžçæ°Žã
次ã«æ°·å·ãã0.5Mçé žæ°ŽçŽ ãããªãŠã 氎溶液
ã§æŽæ»ããåŸãçŽã¡ã«0.1Mçé žæ°ŽçŽ ãããªãŠ
ã 氎溶液ã«æžæ¿ãããããã«äžè¿°ãã粟補æå
氎溶液ãæ·»å ãã宀枩ã§ïŒå€æ¹æããªããåå¿
ãããããçæç©ãã¬ã©ã¹æã§éããå ã
0.1Mçé žæ°ŽçŽ ãããªãŠã 氎溶液ã次ãã§èžç
æ°ŽãæåŸã«çé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH
7.0ïŒã§æŽæ»ããããã®æŽæ»ããåå¿çæç©ã
å åŸ13mmé«ã15cmã®ã¬ã©ã¹ç®¡ã«å å¡«ããŠã¢ãã€
ããã€ã¯ãããã°ã©ãã€çšã«ã©ã ãšããããã®
ã«ã©ã ã«åèšïŒâïŒã®æäœïŒãã ãã¶ã«ã³ãŒã
â180è «ç现èãšã®çµåã«ããæäœã¯çç¥ïŒã§
äœæããæäœæº¶æ¶²ïŒIgGïŒïŒmlãæµå ¥ãã次ã
ã§ïŒïœïŒçé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH
7.0ïŒããã«ã©ã ã®æº¶åºæ¶²ã«èçœãæ€åºãããª
ããªãè¿æµãã次ãã§ã50ïœïŒã°ãªã·ã³âå¡©é ž
ç·©è¡æ°Žæº¶æ¶²ïŒPH4.0ïŒãæ·»å ãã0.5Mé£å¡©æ°Žæº¶
液ãã«ã©ã ã«æµããŠã溶åºããç»åãæ¡åãã
ãããçŽã¡ã«çé žæ°ŽçŽ ãããªãŠã ã§äžæ§ã«ã
ãŠãçé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH7.0ïŒ
ã«å¯ŸããŠ72æééæããïŒ24æéæ¯ã«éæå€æ¶²
ã亀æããïŒãããããŠã«ã©ã ã«ããã¢ãã€ã
ãã€ã¯ãããã°ã©ãã€ãçšããŠç²Ÿè£œããã¶ã«ã³
ãŒãâ180è «çã«å¯Ÿãã粟補æäœæ°Žæº¶æ¶²ãåŸ
ãã ïŒâïŒïŒè «ç现èããã³æ£åžžçŽ°èã«å¯Ÿããé害æ§
è©ŠéšïŒãã®ïŒïŒ äžèšïŒâïŒã§åŸããŠãµã®ã®æã¶ã«ã³ãŒãâ
180è «çå ç«æäœã«ã€ããŠïŒâïŒãšåæ§ãªæ¹æ³
ã§çŽ°èé害æ§è©Šéšãè¡ã€ããçµæã¯äžèšç¬¬ïŒè¡š
ã«ç€ºãã ãªããæ¯èŒãšããŠïŒâïŒã§åŸãæã¶ã«ã³ãŒã
â180è «çæäœã瀺ããã
ãè¡šã
ãã®çµæã¯ãã¢ãã€ããã€ã¯ãããã°ã©ãã€
ãŒ(1)ã«ããæäœã®ç²Ÿè£œã«ãã€ãŠæäœã®ã¶ã«ã³ãŒ
ãâ180现èãžã®æŽ»æ§ãæ Œæ®µã«é«ãŸããèŸçŽ°è
ã«å¯Ÿããæ¯æ§ãäœäžããããšã瀺ããã®ã§ãã¢
ãã€ããã€ã¯ãããã°ã©ãã€ãŒ(1)ã«ãã粟補ã®
åªç§ãã瀺ããŠããã ïŒâïŒïŒæã¶ã«ã³ãŒãâ180æäœãšæè «çå€ãšã®
çµå åèšïŒâïŒããã³ïŒâïŒã§äœè£œããåã ã®æ¹
æ³ã§ç²Ÿè£œãããŠãµã®æã¶ã«ã³ãŒãâ180æäœãš
ãã€ããã€ã·ã³ïŒ£ãããŠãã«ãã·ã³ããã¬ãªã
ã€ã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ãã¶ã«ã³ãã€ã·ã³
ãŸãã¯å¡©é žãããœã«ãã·ã³ã®åã ãšåå¿ããã
ãŠã¢ããçµåã«ããããããã®ååç©ãåæã
ããïŒâïŒã«ããæäœãšãã€ããã€ã·ã³ïŒ£ãšã®
åå¿ã®äŸã次ã«è¿°ã¹ãã ïŒâïŒã§åŸã粟補ãŠãµã®æã¶ã«ã³ãŒãâ180
æäœãïŒmlã®æ°Žäžã«10.4mgãå«æãã氎溶液10
mläžã«13.0mgã®ãã€ããã€ã·ã³ïŒ£ãå ããæ¹æ
äžã«å¡©é žã§ã液ã®PHã4.75ã«èª¿ç¯ãã€ã€ã3.7
mgã®ïŒâãšãã«âïŒâïŒïŒâãžã¡ãã«ã¢ããã
ããã«ïŒâã«ã«ããžã€ããå¡©é žå¡©ãå ããŠäžèš
ã®æéåå¿ãããé ¢é žâé ¢é žãããªãŠã ç·©è¡æ¶²
ïŒPH4.70ïŒïŒmlã®æ·»å ã§åå¿ãåæ¢ãããã次
ãã§åå¿æ¶²ãïŒâã§72æéãïŒã®èžçæ°Žã«å¯Ÿ
ããŠéæïŒãã®éãå€æ¶²ãïŒå亀æããïŒã
ããéæå 液ãæ¿çž®ããåŸã«ãããã¹ããªã³èª
å°äœïŒSephadexGâ25ããã¢ã«ãã·ã¢ã»ãžã€
ãã³ç€Ÿè£œïŒãå å¡«ããçŽåŸ1.5cmé«ã55cmã®ã«
ã©ã ãéããŠãåå¿æ¶²äžã®é«ååéç©è³ªåã³äœ
ååéç©è³ªãå®å šã«åé¢ããã溶åºæ¶²ãè¶ é å¿
åé¢æ©ã§40000ïœÃ60miné å¿åé¢ããŠåŸãã
ãäžæž 液ãâ20âã§åçµä¹Ÿç¥ããŠè£œåããåå
ç©ãåŸããæäœã«å¯Ÿããååå¿æéã«ãããã
ã€ããã€ã·ã³ïŒ£ã®çµåéãã360nïœã®çŽ«å€ç·
åžåãçšããŠæž¬å®ããçµæã¯ç¬¬ïŒè¡šã«ç€ºãããš
ãã§ãã€ãã
ãŒ(1)ã«ããæäœã®ç²Ÿè£œã«ãã€ãŠæäœã®ã¶ã«ã³ãŒ
ãâ180现èãžã®æŽ»æ§ãæ Œæ®µã«é«ãŸããèŸçŽ°è
ã«å¯Ÿããæ¯æ§ãäœäžããããšã瀺ããã®ã§ãã¢
ãã€ããã€ã¯ãããã°ã©ãã€ãŒ(1)ã«ãã粟補ã®
åªç§ãã瀺ããŠããã ïŒâïŒïŒæã¶ã«ã³ãŒãâ180æäœãšæè «çå€ãšã®
çµå åèšïŒâïŒããã³ïŒâïŒã§äœè£œããåã ã®æ¹
æ³ã§ç²Ÿè£œãããŠãµã®æã¶ã«ã³ãŒãâ180æäœãš
ãã€ããã€ã·ã³ïŒ£ãããŠãã«ãã·ã³ããã¬ãªã
ã€ã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ãã¶ã«ã³ãã€ã·ã³
ãŸãã¯å¡©é žãããœã«ãã·ã³ã®åã ãšåå¿ããã
ãŠã¢ããçµåã«ããããããã®ååç©ãåæã
ããïŒâïŒã«ããæäœãšãã€ããã€ã·ã³ïŒ£ãšã®
åå¿ã®äŸã次ã«è¿°ã¹ãã ïŒâïŒã§åŸã粟補ãŠãµã®æã¶ã«ã³ãŒãâ180
æäœãïŒmlã®æ°Žäžã«10.4mgãå«æãã氎溶液10
mläžã«13.0mgã®ãã€ããã€ã·ã³ïŒ£ãå ããæ¹æ
äžã«å¡©é žã§ã液ã®PHã4.75ã«èª¿ç¯ãã€ã€ã3.7
mgã®ïŒâãšãã«âïŒâïŒïŒâãžã¡ãã«ã¢ããã
ããã«ïŒâã«ã«ããžã€ããå¡©é žå¡©ãå ããŠäžèš
ã®æéåå¿ãããé ¢é žâé ¢é žãããªãŠã ç·©è¡æ¶²
ïŒPH4.70ïŒïŒmlã®æ·»å ã§åå¿ãåæ¢ãããã次
ãã§åå¿æ¶²ãïŒâã§72æéãïŒã®èžçæ°Žã«å¯Ÿ
ããŠéæïŒãã®éãå€æ¶²ãïŒå亀æããïŒã
ããéæå 液ãæ¿çž®ããåŸã«ãããã¹ããªã³èª
å°äœïŒSephadexGâ25ããã¢ã«ãã·ã¢ã»ãžã€
ãã³ç€Ÿè£œïŒãå å¡«ããçŽåŸ1.5cmé«ã55cmã®ã«
ã©ã ãéããŠãåå¿æ¶²äžã®é«ååéç©è³ªåã³äœ
ååéç©è³ªãå®å šã«åé¢ããã溶åºæ¶²ãè¶ é å¿
åé¢æ©ã§40000ïœÃ60miné å¿åé¢ããŠåŸãã
ãäžæž 液ãâ20âã§åçµä¹Ÿç¥ããŠè£œåããåå
ç©ãåŸããæäœã«å¯Ÿããååå¿æéã«ãããã
ã€ããã€ã·ã³ïŒ£ã®çµåéãã360nïœã®çŽ«å€ç·
åžåãçšããŠæž¬å®ããçµæã¯ç¬¬ïŒè¡šã«ç€ºãããš
ãã§ãã€ãã
ãè¡šã
ããã«åŸãããæ¬çºæã®ååç©ã®ïŒã€ã¯ãå
åéçŽ150000ã®ä¿®é£Ÿèçœè³ªã§ãã€ãŠãæ°Žã«å¯
溶ããã³ãŒã³ãã¢ã»ãã³ããã³ã¡ã¿ããŒã«çã®
ææ©æº¶åªã«äžæº¶ã§ããããã®ååç©ã®èµ€å€ç·åž
åã¹ãã¯ãã«ã¯æ·»ä»å³é¢ã®ããšãã§ãã€ãã玫
å€ç·åžåããŒã¯ã枬å®ããŠ280ãš360nïœã«ç¹åŸŽ
çãªåžåãåŸãã äžèšã®æäœã«æºããŠã粟補ãŠãµã®æã¶ã«ã³ãŒ
ãâ180æäœ10mgãšå¡©é žãããœã«ãã·ã³ãããŠ
ãã«ãã·ã³ãããã³ã¢ã¯ãããã€ã·ã³ïŒ€ã®ãã
ãããšãåå¿ããããŠãçŽïŒmgã®çµåååç©ã
åŸããå¡©é žãããœã«ãã·ã³ã®æäœèçœïŒmgïŒåœ
ãã®çµåéã¯åå¿æé10åããã³30åã®éãã
ãã4.1ÎŒïœãš9.1ÎŒïœã§ãã€ãã 次ã«ïŒâïŒã§åŸã粟補ãŠãµã®æã¶ã«ã³ãŒãâ
180æäœãšãã€ããã€ã·ã³ïŒ£ãšãåèšãšåæ§ãª
æ¡ä»¶ã§åå¿ããããŠãåèšãšæ®ãã©åæ§ãªç©
çã»ååŠçæ§è³ªã瀺ãååç©ãåŸããããã«æº
ããŠããŠãã«ãã·ã³ããã¬ãªãã€ã·ã³ãã¢ã¯ã
ããã€ã·ã³ïŒ€ãã¶ã«ã³ãã€ã·ã³ããã³å¡©é žãã
ãœã«ãã·ã³ã®ãããããšã®ååç©ããåæã
ãã å®æœäŸ ïŒ ïŒâïŒïŒè «ç现èã«å¯Ÿããæäœã®èª¿è£œãšç²Ÿè£œ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ãã次ãã§ãã€
ããã€ã·ã³ïŒ£ã«ãã€ãŠå¢æ®èœããªãããè ¹æ°Žå
ã¶ã«ã³ãŒãâ180è «ç现è107åãïŒé±éæ¯ã«ïŒ
åãäžå¹ã®ICRããŠã¹ã®è ¹è å ã«æ¥çš®ããïŒå
ç®ã®æ¥çš®ã®ïŒæ¥ç®ã«ãããŠã¹ã麻é ããŠéè ¹ã
è ¹éšå€§éèããæ¡è¡ããããããæäœãå«ãæ
è¡æž ã調補ãããããããŠ100å¹ã®ããŠã¹ãã
53mlã®æè¡æž ãåŸããæè¡æž ããæäœã®æ¡åã
ãã³æäœã®ç²Ÿè£œã¯ïŒâïŒã«æºããŠè¡ããããŠã¹
ã®è¡çã«ããåžåãŸã§ã§åããã ïŒâïŒïŒã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒ(1)ã«ã
ãæäœã®ç²Ÿè£œ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ããè ¹æ°Žåã¶ã«
ã³ãŒãâ180è «ç现èãåçµä¹Ÿç¥ãããã®ãã®
30ïœã«ïŒïœïŒçé žã«ãªãŠã ç·©è¡æ¶²ã§ç·©è¡ãã
3MKCl溶液ïŒPH7.4ïŒãå ããŠæåã®æœåºã20
æéè¡ã€ãããã®æœåºæ¶²ã65000Gã§10åéé
å¿åé¢ããŠäžæž ãæ¡åããæŽã«ãã®äžæž ã
180000Gã§30åéé å¿åé¢ããŠäžæž ãæ¡åã
ãŠããããèžçæ°Žã«å¯ŸãïŒâã§72æééæãã
ïŒãã®éã24æéæ¯ã«éæå€æ¶²ã亀æããïŒãã
ãããŠåŸãã¶ã«ã³ãŒãâ180è «çæåã«ããã¢
ãã€ããã€ã¯ãããã°ã©ãã€ã¯æ¬¡ã®ããšãè¡ã€
ãã å ããã¢ã¬ããŒã¹ã²ã«ïŒSepharose4BïŒ
Pharmacia Japan Co Ltdã®è£œåïŒãæ°Žã§èšæœ€
ãããŠ20mlãšããããã«ãïŒïœïŒmlã®ããã ã·
ã¢ã³æ°Žæº¶æ¶²20mlãå ããŠãPHã11.0ã«ä¿ã¡ã€ã€
äž¡è ãïŒåéåå¿ãããŠããåå¿ç©ãã¬ã©ã¹
æã§éããæ²æŸ±ãæäžã§æ°·å·ããèžçæ°Žã
次ã«æ°·å·ãã0.5Mçé žæ°ŽçŽ ãããªãŠã 氎溶液
ã§æŽæ»ããåŸãçŽã¡ã«0.1Mçé žæ°ŽçŽ ãããªãŠ
ã 氎溶液ã«æžæ¿ãããããã«äžè¿°ãã粟補æå
氎溶液ãæ·»å ãã宀枩ã§ïŒå€æ¹æããªããåå¿
ãããããçæç©ãã¬ã©ã¹éããå ãã
0.1Mçé žæ°ŽçŽ ãããªãŠã 氎溶液ã次ãã§èžæº
æ°ŽãæåŸã«çé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH
7.0ïŒã§æŽæ»ããããã®æŽæ»ããåå¿çæç©ã
å åŸ13mmé«ã15cmã®ã¬ã©ã¹ç®¡ã«å å¡«ããŠã¢ãã€
ããã€ã¯ãããã°ã©ãã€çšã«ã©ã ãšããã åèšïŒâïŒã®æäœã§äœã€ãæè¡æž ïŒæäœãå«
ãïŒæº¶æ¶²ïŒmlãäžèšã®ã¢ãã€ããã€ã¯ãããã°
ã©ãã€çšã«ã©ã ã«æµå ¥ãã次ãã§ïŒïœïŒçé žå¡©
ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH7.0ïŒããã«ã©ã
ã®æº¶åºæ¶²ã«èçœãæ€åºãããªããªãè¿æµãã次
ãã§ã50ïœïŒã°ãªã·ã³âå¡©é žç·©è¡æ°Žæº¶æ¶²ïŒPH
4.0ïŒãæ·»å ãã0.5Mé£å¡©æ°Žæº¶æ¶²ãã«ã©ã ã«æµ
ããŠã溶åºããç»åãæ¡åãããããçŽã¡ã«ç
é žæ°ŽçŽ ãããªãŠã ã§äžæ§ã«ããŠãçé žå¡©ç·©è¡é£
塩氎溶液ïŒ0.85ïŒ ãPH7.0ïŒã«å¯ŸããŠ72æéé
æããïŒ24æéæ¯ã«éæå€æ¶²ã亀æããïŒãã
ãããŠã¢ãã€ããã€ã¯ãããã°ã©ãã€ãçšããŠ
粟補ããã¶ã«ã³ãŒãâ180è «çã«å¯Ÿããæäœæ°Ž
溶液ãåŸãã ïŒâïŒïŒè «ç现èããã³æ£åžžçŽ°èã«å¯Ÿããé害æ§
è©Šéš äžèšïŒâïŒã§åŸãããŠã¹ã®æã¶ã«ã³ãŒãâ
180è «çå ç«æäœã«ã€ããŠå®æœäŸïŒãšåæ§ãªæ¹
æ³ã§çŽ°èé害æ§è©Šéšãè¡ã€ããçµæã¯äžèšç¬¬ïŒ
è¡šã«ç€ºãã
åéçŽ150000ã®ä¿®é£Ÿèçœè³ªã§ãã€ãŠãæ°Žã«å¯
溶ããã³ãŒã³ãã¢ã»ãã³ããã³ã¡ã¿ããŒã«çã®
ææ©æº¶åªã«äžæº¶ã§ããããã®ååç©ã®èµ€å€ç·åž
åã¹ãã¯ãã«ã¯æ·»ä»å³é¢ã®ããšãã§ãã€ãã玫
å€ç·åžåããŒã¯ã枬å®ããŠ280ãš360nïœã«ç¹åŸŽ
çãªåžåãåŸãã äžèšã®æäœã«æºããŠã粟補ãŠãµã®æã¶ã«ã³ãŒ
ãâ180æäœ10mgãšå¡©é žãããœã«ãã·ã³ãããŠ
ãã«ãã·ã³ãããã³ã¢ã¯ãããã€ã·ã³ïŒ€ã®ãã
ãããšãåå¿ããããŠãçŽïŒmgã®çµåååç©ã
åŸããå¡©é žãããœã«ãã·ã³ã®æäœèçœïŒmgïŒåœ
ãã®çµåéã¯åå¿æé10åããã³30åã®éãã
ãã4.1ÎŒïœãš9.1ÎŒïœã§ãã€ãã 次ã«ïŒâïŒã§åŸã粟補ãŠãµã®æã¶ã«ã³ãŒãâ
180æäœãšãã€ããã€ã·ã³ïŒ£ãšãåèšãšåæ§ãª
æ¡ä»¶ã§åå¿ããããŠãåèšãšæ®ãã©åæ§ãªç©
çã»ååŠçæ§è³ªã瀺ãååç©ãåŸããããã«æº
ããŠããŠãã«ãã·ã³ããã¬ãªãã€ã·ã³ãã¢ã¯ã
ããã€ã·ã³ïŒ€ãã¶ã«ã³ãã€ã·ã³ããã³å¡©é žãã
ãœã«ãã·ã³ã®ãããããšã®ååç©ããåæã
ãã å®æœäŸ ïŒ ïŒâïŒïŒè «ç现èã«å¯Ÿããæäœã®èª¿è£œãšç²Ÿè£œ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ãã次ãã§ãã€
ããã€ã·ã³ïŒ£ã«ãã€ãŠå¢æ®èœããªãããè ¹æ°Žå
ã¶ã«ã³ãŒãâ180è «ç现è107åãïŒé±éæ¯ã«ïŒ
åãäžå¹ã®ICRããŠã¹ã®è ¹è å ã«æ¥çš®ããïŒå
ç®ã®æ¥çš®ã®ïŒæ¥ç®ã«ãããŠã¹ã麻é ããŠéè ¹ã
è ¹éšå€§éèããæ¡è¡ããããããæäœãå«ãæ
è¡æž ã調補ãããããããŠ100å¹ã®ããŠã¹ãã
53mlã®æè¡æž ãåŸããæè¡æž ããæäœã®æ¡åã
ãã³æäœã®ç²Ÿè£œã¯ïŒâïŒã«æºããŠè¡ããããŠã¹
ã®è¡çã«ããåžåãŸã§ã§åããã ïŒâïŒïŒã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒ(1)ã«ã
ãæäœã®ç²Ÿè£œ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ããè ¹æ°Žåã¶ã«
ã³ãŒãâ180è «ç现èãåçµä¹Ÿç¥ãããã®ãã®
30ïœã«ïŒïœïŒçé žã«ãªãŠã ç·©è¡æ¶²ã§ç·©è¡ãã
3MKCl溶液ïŒPH7.4ïŒãå ããŠæåã®æœåºã20
æéè¡ã€ãããã®æœåºæ¶²ã65000Gã§10åéé
å¿åé¢ããŠäžæž ãæ¡åããæŽã«ãã®äžæž ã
180000Gã§30åéé å¿åé¢ããŠäžæž ãæ¡åã
ãŠããããèžçæ°Žã«å¯ŸãïŒâã§72æééæãã
ïŒãã®éã24æéæ¯ã«éæå€æ¶²ã亀æããïŒãã
ãããŠåŸãã¶ã«ã³ãŒãâ180è «çæåã«ããã¢
ãã€ããã€ã¯ãããã°ã©ãã€ã¯æ¬¡ã®ããšãè¡ã€
ãã å ããã¢ã¬ããŒã¹ã²ã«ïŒSepharose4BïŒ
Pharmacia Japan Co Ltdã®è£œåïŒãæ°Žã§èšæœ€
ãããŠ20mlãšããããã«ãïŒïœïŒmlã®ããã ã·
ã¢ã³æ°Žæº¶æ¶²20mlãå ããŠãPHã11.0ã«ä¿ã¡ã€ã€
äž¡è ãïŒåéåå¿ãããŠããåå¿ç©ãã¬ã©ã¹
æã§éããæ²æŸ±ãæäžã§æ°·å·ããèžçæ°Žã
次ã«æ°·å·ãã0.5Mçé žæ°ŽçŽ ãããªãŠã 氎溶液
ã§æŽæ»ããåŸãçŽã¡ã«0.1Mçé žæ°ŽçŽ ãããªãŠ
ã 氎溶液ã«æžæ¿ãããããã«äžè¿°ãã粟補æå
氎溶液ãæ·»å ãã宀枩ã§ïŒå€æ¹æããªããåå¿
ãããããçæç©ãã¬ã©ã¹éããå ãã
0.1Mçé žæ°ŽçŽ ãããªãŠã 氎溶液ã次ãã§èžæº
æ°ŽãæåŸã«çé žå¡©ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH
7.0ïŒã§æŽæ»ããããã®æŽæ»ããåå¿çæç©ã
å åŸ13mmé«ã15cmã®ã¬ã©ã¹ç®¡ã«å å¡«ããŠã¢ãã€
ããã€ã¯ãããã°ã©ãã€çšã«ã©ã ãšããã åèšïŒâïŒã®æäœã§äœã€ãæè¡æž ïŒæäœãå«
ãïŒæº¶æ¶²ïŒmlãäžèšã®ã¢ãã€ããã€ã¯ãããã°
ã©ãã€çšã«ã©ã ã«æµå ¥ãã次ãã§ïŒïœïŒçé žå¡©
ç·©è¡é£å¡©æ°Žæº¶æ¶²ïŒ0.85ïŒ ãPH7.0ïŒããã«ã©ã
ã®æº¶åºæ¶²ã«èçœãæ€åºãããªããªãè¿æµãã次
ãã§ã50ïœïŒã°ãªã·ã³âå¡©é žç·©è¡æ°Žæº¶æ¶²ïŒPH
4.0ïŒãæ·»å ãã0.5Mé£å¡©æ°Žæº¶æ¶²ãã«ã©ã ã«æµ
ããŠã溶åºããç»åãæ¡åãããããçŽã¡ã«ç
é žæ°ŽçŽ ãããªãŠã ã§äžæ§ã«ããŠãçé žå¡©ç·©è¡é£
塩氎溶液ïŒ0.85ïŒ ãPH7.0ïŒã«å¯ŸããŠ72æéé
æããïŒ24æéæ¯ã«éæå€æ¶²ã亀æããïŒãã
ãããŠã¢ãã€ããã€ã¯ãããã°ã©ãã€ãçšããŠ
粟補ããã¶ã«ã³ãŒãâ180è «çã«å¯Ÿããæäœæ°Ž
溶液ãåŸãã ïŒâïŒïŒè «ç现èããã³æ£åžžçŽ°èã«å¯Ÿããé害æ§
è©Šéš äžèšïŒâïŒã§åŸãããŠã¹ã®æã¶ã«ã³ãŒãâ
180è «çå ç«æäœã«ã€ããŠå®æœäŸïŒãšåæ§ãªæ¹
æ³ã§çŽ°èé害æ§è©Šéšãè¡ã€ããçµæã¯äžèšç¬¬ïŒ
è¡šã«ç€ºãã
ãè¡šã
ãè¡šã
第ïŒè¡šã§ãããããã«ãåè¿°ãšåæ§ã¢ãã€ã
ãã€ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠã¶ã«ã³ãŒãâ
180现èãžã®æŽ»æ§ã¯æ Œæ®µã«å¢å€§ããŠããã ïŒâïŒïŒããŠã¹æã¶ã«ã³ãŒãâ180æäœãšæè «ç
å€ãšã®çµå ïŒâïŒããã³ïŒâïŒã§åŸãããŠã¹æã¶ã«ã³ãŒ
ãâ180æäœãšãã€ããã€ã·ã³ïŒ£ãšãåèšïŒâ
ïŒã§è¿°ã¹ãæ¹æ³ã§çµåããããŠãäž¡è ãã¢ãã
åºã§çµåããååç©ãåŸããåæ§ã®æ¹æ³ã§å¡©é ž
ãããœã«ãã·ã³ããã¬ãªãã€ã·ã³ãããŠãã«ã
ã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³ã¶ã«ã³ãã€ã·
ã³ã®ãããããšæäœãšãã¢ããçµåã«ãã€ãŠçµ
åããååç©ãåŸãã ãããã®ååç©ã¯äœããåèšïŒâïŒã§åŸã察
å¿ååç©ãšæ®ã©åäžã®ç©çã»ååŠçæ§è³ªã瀺ã
ãã å®æœäŸ ïŒ ã¶ã«ã³ãŒãâ180åºåè «çã«å¯Ÿããæè «çå¹æ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ããããŠã¹ã¶ã«ã³
ãŒãâ180è «ç现èã10å¹ãããªãå矀ã®åICR
ããŠã¹ã®è äžéšã®ç®äžã«ãïŒÃ106åïŒå¹ç§»æ€
ãã移æ€ã®24æéåŸããåçš®æäœãååžè²©æè «ç
å€ããŠãµã®æã¶ã«ã³ãŒãâ180æäœãšåçš®åžè²©æ
è «çå€ãšã®ååç©ããã³ããŠã¹æã¶ã«ã³ãŒãâ
180æäœãšåçš®åžè²©æè «çå€ãšã®ååç©ã®ããã
ãã®æ°Žæº¶æ¶²ãïŒæ¥çœ®ã«ïŒåãåèšã§10ååããŠã¹
ã®è ¹è å ã«æ³šå°ããæåŸã®æ³šå°ã®ïŒæ¥åŸã«ããŠã¹
ã殺ããŠè «çãæåºããŠç§€éã10å¹ã«ã€ããŠã®å¹³
åå€ãæ±ããããã®å¹³åè «çééããååç©æ°Ž
溶液ã®ä»£ãã«çççé£å¡©æ°Žã10åæäžããå¯Ÿç §çŸ€
ã©ãã10å¹ã®å¹³åè «çééãšæ¯èŒããããšã«ã
ã€ãŠãæ¬çºæååç©ã®è «çå¢æ®æå¶çãïŒïŒâ
ïŒïŒ£ïŒÃ100ãšããŠç¬¬ïŒãïŒãïŒããã³ïŒè¡šã«ç€ºãã 第ïŒè¡šã¯ãã€ããã€ã·ã³ïŒ£ãšã§åæããååç©ã
第ïŒè¡šã¯ãã¬ãªãã€ã·ã³ãšã§åæããååç©ã第
ïŒè¡šã¯å¡©é žãããœã«ãã·ã³ãšã§åæããååç©ã
第ïŒè¡šã¯æäœã®æäžã«ããçµæã§ããã
ãã€ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠã¶ã«ã³ãŒãâ
180现èãžã®æŽ»æ§ã¯æ Œæ®µã«å¢å€§ããŠããã ïŒâïŒïŒããŠã¹æã¶ã«ã³ãŒãâ180æäœãšæè «ç
å€ãšã®çµå ïŒâïŒããã³ïŒâïŒã§åŸãããŠã¹æã¶ã«ã³ãŒ
ãâ180æäœãšãã€ããã€ã·ã³ïŒ£ãšãåèšïŒâ
ïŒã§è¿°ã¹ãæ¹æ³ã§çµåããããŠãäž¡è ãã¢ãã
åºã§çµåããååç©ãåŸããåæ§ã®æ¹æ³ã§å¡©é ž
ãããœã«ãã·ã³ããã¬ãªãã€ã·ã³ãããŠãã«ã
ã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³ã¶ã«ã³ãã€ã·
ã³ã®ãããããšæäœãšãã¢ããçµåã«ãã€ãŠçµ
åããååç©ãåŸãã ãããã®ååç©ã¯äœããåèšïŒâïŒã§åŸã察
å¿ååç©ãšæ®ã©åäžã®ç©çã»ååŠçæ§è³ªã瀺ã
ãã å®æœäŸ ïŒ ã¶ã«ã³ãŒãâ180åºåè «çã«å¯Ÿããæè «çå¹æ ICRããŠã¹ãçšããŠç¶ä»£å¹é€ããããŠã¹ã¶ã«ã³
ãŒãâ180è «ç现èã10å¹ãããªãå矀ã®åICR
ããŠã¹ã®è äžéšã®ç®äžã«ãïŒÃ106åïŒå¹ç§»æ€
ãã移æ€ã®24æéåŸããåçš®æäœãååžè²©æè «ç
å€ããŠãµã®æã¶ã«ã³ãŒãâ180æäœãšåçš®åžè²©æ
è «çå€ãšã®ååç©ããã³ããŠã¹æã¶ã«ã³ãŒãâ
180æäœãšåçš®åžè²©æè «çå€ãšã®ååç©ã®ããã
ãã®æ°Žæº¶æ¶²ãïŒæ¥çœ®ã«ïŒåãåèšã§10ååããŠã¹
ã®è ¹è å ã«æ³šå°ããæåŸã®æ³šå°ã®ïŒæ¥åŸã«ããŠã¹
ã殺ããŠè «çãæåºããŠç§€éã10å¹ã«ã€ããŠã®å¹³
åå€ãæ±ããããã®å¹³åè «çééããååç©æ°Ž
溶液ã®ä»£ãã«çççé£å¡©æ°Žã10åæäžããå¯Ÿç §çŸ€
ã©ãã10å¹ã®å¹³åè «çééãšæ¯èŒããããšã«ã
ã€ãŠãæ¬çºæååç©ã®è «çå¢æ®æå¶çãïŒïŒâ
ïŒïŒ£ïŒÃ100ãšããŠç¬¬ïŒãïŒãïŒããã³ïŒè¡šã«ç€ºãã 第ïŒè¡šã¯ãã€ããã€ã·ã³ïŒ£ãšã§åæããååç©ã
第ïŒè¡šã¯ãã¬ãªãã€ã·ã³ãšã§åæããååç©ã第
ïŒè¡šã¯å¡©é žãããœã«ãã·ã³ãšã§åæããååç©ã
第ïŒè¡šã¯æäœã®æäžã«ããçµæã§ããã
ãè¡šã
ãè¡šã
ãè¡šã
ã©ãã€ãŒ(3)åã¯(1)ã§ç²Ÿè£œããæäœãåžè²©æ
è «çå€ãšçµåããŠåæãããã®
è «çå€ãšçµåããŠåæãããã®
ãè¡šã
(1)ã§ç²Ÿè£œããæäœ
äžèšç¬¬ïŒãïŒè¡šã§å€ãããšããæ¬ååç©ã®ã¶ã«
ã³ãŒãâ180å¢æ®æå¶çã¯ãæ姿ã§ã¯ãåžè²©ã®æ
è «çå€ã®ïŒã10åã®æäžéã§ãã»ãŒåžè²©æè «çå€
ã®æå¶çãšçããããã®ããšã¯ç¬¬ïŒè¡šãããå€ã
ããšãããã®çšåºŠã®æäžéã§ã¯æäœèªèº«ã®è «çæ
å¶åãã»ãšãã©çŸããªãããšã瀺ããã®ã§ãã€
ãŠãåœç¶ã®ããšã§ãããæ¬ååç©ã®ç¹åŸŽã¯ãæ¬å
åç©ã®æåã§ããåžè²©æè «çå€ã®æäžéãšãæ¬å
åç©æäžã«ããåžè²©æè «çå€æåã®æäžéãæ¯èŒ
ãããšå€ç¶ãšããã®ã§ãã€ãŠãåŸè ã¯åè ã®1/10
ã1/20ã«éããªãã®ã«ãæ®ãã©åè ãšåçšåºŠã®è «
çå¢æ®æå¶çã瀺ããŠããããã®äºã¯æ¬ååç©ã®
æåã®ïŒã€ã§ããæäœããä»ã®æåã§ããå°éåž
販æè «çå€ãåŠäœã«è¯ãè «çéšäœã«å°éããããŠ
ãããã瀺ããã®ã«å€ãªãããæ¬çºæã®çæ³ãã¿
ããšã«å ·äœåããŠããã æ¬ååç©ã¯ãã®äœçšã«ãã€ãŠãå æ¥å¯äœçšã®æ¥µ
床ã«é«ãåžè²©æè «çå€ã®äœ¿çšãåŸæ¥ã®1/10ã1/20
ã«äœäžããªããããã€åŸæ¥ãšåçšåºŠã®è «çå¢æ®æ
å¶åãçºæ®ããã®ã§ããã å°ç¹èšãã¹ãã¯ãè «çå¢æ®æå¶çã®ç¹ã§ã¯æäœ
ã®ç±æ¥ã¯é¢ä¿ãªããããŠãµã®ãçšããŠèª¿è£œã粟補
ããæäœãšåžè²©æè «çå€ãšã®ååç©ãããŠã¹ã«æ
äžããå Žåã«ã10å¹ã®ããŠã¹ã®å ïŒå¹çšåºŠã¯å šèº«
çæ£ããã³ç¡¬çŽãªã©ã®ã¢ããã©ãã·ãŒã·ãšãã¯ã
åããããŠãµã®ãçšããŠèª¿è£œããã¢ãã€ããã€ã¯
ãããã°ã©ãã€ãŒã§ç²Ÿè£œããæäœãçšããŠåæã
ãååç©ãæäžããå Žåã«ã¯ããã®ãããªã¢ãã
ã©ãã·ãŒã·ãšãã¯ã®çºçã¯å€§ãã«è»œæžããããã
ãŠã¹ãçšããŠäœæã»ç²Ÿè£œããæäœãçšããŠåæã
ãååç©ã®å Žåã«ã¯ãã¢ããã©ãã·ãŒã·ãšãã¯ã®
çºçã¯æ¥µããŠçšã§ãã€ãããæŽã«ãã®æäœã®ç²Ÿè£œ
ãã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠè¡ã€
ãå Žåã®ååç©ã§ã¯ã¢ããã©ãã·ãŒã·ãšãã¯ã®çº
çã¯å šãèŠããããã€ãã
äžèšç¬¬ïŒãïŒè¡šã§å€ãããšããæ¬ååç©ã®ã¶ã«
ã³ãŒãâ180å¢æ®æå¶çã¯ãæ姿ã§ã¯ãåžè²©ã®æ
è «çå€ã®ïŒã10åã®æäžéã§ãã»ãŒåžè²©æè «çå€
ã®æå¶çãšçããããã®ããšã¯ç¬¬ïŒè¡šãããå€ã
ããšãããã®çšåºŠã®æäžéã§ã¯æäœèªèº«ã®è «çæ
å¶åãã»ãšãã©çŸããªãããšã瀺ããã®ã§ãã€
ãŠãåœç¶ã®ããšã§ãããæ¬ååç©ã®ç¹åŸŽã¯ãæ¬å
åç©ã®æåã§ããåžè²©æè «çå€ã®æäžéãšãæ¬å
åç©æäžã«ããåžè²©æè «çå€æåã®æäžéãæ¯èŒ
ãããšå€ç¶ãšããã®ã§ãã€ãŠãåŸè ã¯åè ã®1/10
ã1/20ã«éããªãã®ã«ãæ®ãã©åè ãšåçšåºŠã®è «
çå¢æ®æå¶çã瀺ããŠããããã®äºã¯æ¬ååç©ã®
æåã®ïŒã€ã§ããæäœããä»ã®æåã§ããå°éåž
販æè «çå€ãåŠäœã«è¯ãè «çéšäœã«å°éããããŠ
ãããã瀺ããã®ã«å€ãªãããæ¬çºæã®çæ³ãã¿
ããšã«å ·äœåããŠããã æ¬ååç©ã¯ãã®äœçšã«ãã€ãŠãå æ¥å¯äœçšã®æ¥µ
床ã«é«ãåžè²©æè «çå€ã®äœ¿çšãåŸæ¥ã®1/10ã1/20
ã«äœäžããªããããã€åŸæ¥ãšåçšåºŠã®è «çå¢æ®æ
å¶åãçºæ®ããã®ã§ããã å°ç¹èšãã¹ãã¯ãè «çå¢æ®æå¶çã®ç¹ã§ã¯æäœ
ã®ç±æ¥ã¯é¢ä¿ãªããããŠãµã®ãçšããŠèª¿è£œã粟補
ããæäœãšåžè²©æè «çå€ãšã®ååç©ãããŠã¹ã«æ
äžããå Žåã«ã10å¹ã®ããŠã¹ã®å ïŒå¹çšåºŠã¯å šèº«
çæ£ããã³ç¡¬çŽãªã©ã®ã¢ããã©ãã·ãŒã·ãšãã¯ã
åããããŠãµã®ãçšããŠèª¿è£œããã¢ãã€ããã€ã¯
ãããã°ã©ãã€ãŒã§ç²Ÿè£œããæäœãçšããŠåæã
ãååç©ãæäžããå Žåã«ã¯ããã®ãããªã¢ãã
ã©ãã·ãŒã·ãšãã¯ã®çºçã¯å€§ãã«è»œæžããããã
ãŠã¹ãçšããŠäœæã»ç²Ÿè£œããæäœãçšããŠåæã
ãååç©ã®å Žåã«ã¯ãã¢ããã©ãã·ãŒã·ãšãã¯ã®
çºçã¯æ¥µããŠçšã§ãã€ãããæŽã«ãã®æäœã®ç²Ÿè£œ
ãã¢ãã€ããã€ã¯ãããã°ã©ãã€ãŒã«ãã€ãŠè¡ã€
ãå Žåã®ååç©ã§ã¯ã¢ããã©ãã·ãŒã·ãšãã¯ã®çº
çã¯å šãèŠããããã€ãã
æ·»ä»å³é¢ã¯æ¬çºæã®æè
«çå€ã®æå¹æåã§ãã
ååç©ã®äžäŸã«ã€ããŠã®èµ€å€ç·åžåã¹ãã¯ãã«ã
瀺ãããã®ã§ããã
ååç©ã®äžäŸã«ã€ããŠã®èµ€å€ç·åžåã¹ãã¯ãã«ã
瀺ãããã®ã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ è «çæåãçµåãããã¢ãã€ããã€ãŒã¯ãã
ãã°ã©ãã€ãŒã«ãã粟補ãããè «çæåã«å¯Ÿãã
åçš®æäœãšãå°ãªããšãïŒåã®ã¢ããåºãããã¯
ã«ã«ããã·ã«åºãæããæè «çæ§æçç©è³ªãã¢ã
ãçµåããŠãªãååç©ãæå¹æåãšããæè «ç
å€ã ïŒ åçš®æäœããã¶ã«ã³ãŒã180ãäœè€èºçã
â1210çœè¡ç ãâ388çœè¡ç ããšãŒãªããçã
åç°èè «ãæ¥æ§ãªã³ãæ§çœè¡ç ã骚é«çãããã¯
ãã®ä»ã®äººçããéžã°ããè «çã®æåããèªèµ·ã
ããå ç«ã°ãããªã³ç»åãè «çæåãçµåããã
ã¢ãã€ããã€ãŒã¯ãããã°ã©ãã€ãŒã«ãã粟補ã
ããã®ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®æè «çå€ã ïŒ æè «çæ§æçç©è³ªãããã€ããã€ã·ã³ïŒ£ãå¡©
é žãããœã«ãã·ã³ããã¬ãªãã€ã·ã³ãããŠãã«ã
ã·ã³ãã¢ã¯ãããã€ã·ã³ïŒ€ããã³ã¶ã«ã³ãã€ã·ã³
ãããªã矀ããéžæãããããšãç¹åŸŽãšããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®æè «çå€ã ïŒ ååç©ããåçš®æäœïŒåååœãæè «çæ§æç
ç©è³ªãïŒä¹è³ïŒååçµåãããã®ã§ããããšãç¹
城ãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ããã
ãã«èšèŒã®æè «çå€ã ïŒ æ³šå°å€åœ¢æ ã«ããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ããããã«èšèŒã®æè «ç
å€ã
Priority Applications (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16138878A JPS5592325A (en) | 1978-12-29 | 1978-12-29 | Antitumor agent and its preparation |
| US06/103,474 US4315851A (en) | 1978-12-29 | 1979-12-14 | Pharmaceutical composition having antitumor activity |
| SE7910483A SE7910483L (sv) | 1978-12-29 | 1979-12-19 | Farmaceutisk komposition med tumorhemmande effekt |
| ZA00796896A ZA796896B (en) | 1978-12-29 | 1979-12-19 | Pharmaceutical composition having antitumor activity |
| PH23447A PH16902A (en) | 1978-12-29 | 1979-12-20 | Pharmaceutical composition having anti-tumor activity |
| AU54144/79A AU518952B2 (en) | 1978-12-29 | 1979-12-21 | Antitumour composition |
| BE6/47054A BE880970A (fr) | 1978-12-29 | 1979-12-28 | Composition pharmaceutique ayant une activite antitumorale |
| FR797932054A FR2445149B1 (fr) | 1978-12-29 | 1979-12-28 | Composition pharmaceutique ayant une activite antitumorale |
| GB7944494A GB2038836B (en) | 1978-12-29 | 1979-12-28 | Antitumour substance |
| CH11501/79A CH655010A5 (de) | 1978-12-29 | 1979-12-28 | Pharmazeutischer wirkstoff mit antitumoraktivitaet. |
| DE2952690A DE2952690C2 (de) | 1978-12-29 | 1979-12-29 | Antitumorsubstanz, Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Mittel |
| IT28464/79A IT1127324B (it) | 1978-12-29 | 1979-12-31 | Composizione farmaceutica avente attivita' antitumorale |
| US06/321,486 US4401592A (en) | 1978-12-29 | 1981-11-16 | Pharmaceutical composition having antitumor activity |
| SE8406510A SE8406510D0 (sv) | 1978-12-29 | 1984-12-20 | Farmaceutisk komposition med tumorhemmande effekt |
| SE8406511A SE8406511D0 (sv) | 1978-12-29 | 1984-12-20 | Farmaceutisk komposition med tumorhemmande effekt |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16138878A JPS5592325A (en) | 1978-12-29 | 1978-12-29 | Antitumor agent and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5592325A JPS5592325A (en) | 1980-07-12 |
| JPS6254086B2 true JPS6254086B2 (ja) | 1987-11-13 |
Family
ID=15734135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16138878A Granted JPS5592325A (en) | 1978-12-29 | 1978-12-29 | Antitumor agent and its preparation |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JPS5592325A (ja) |
| AU (1) | AU518952B2 (ja) |
| BE (1) | BE880970A (ja) |
| ZA (1) | ZA796896B (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5665828A (en) * | 1979-11-02 | 1981-06-03 | Kureha Chem Ind Co Ltd | Antitumor agent |
| JPS58118520A (ja) * | 1982-01-09 | 1983-07-14 | Hidematsu Hirai | æè «çæ§èçœè€åäœããã³ãã®è£œé æ³ |
| US4448663A (en) * | 1982-07-06 | 1984-05-15 | The Dow Chemical Company | Double L-shaped electrode for brine electrolysis cell |
| JPH0651643B2 (ja) * | 1983-01-19 | 1994-07-06 | åžäººæ ªåŒäŒç€Ÿ | 殺现èæ§ä¿®é£Ÿå ç«ã°ãããªã³åã³ãã®è£œé æ¹æ³ |
| JPH0611713B2 (ja) * | 1983-04-08 | 1994-02-16 | å矜ååŠå·¥æ¥æ ªåŒäŒç€Ÿ | ããå ç«ã°ãããªã³çµåæè «çå€ |
| JPS6041617A (ja) * | 1983-08-18 | 1985-03-05 | Teijin Ltd | 殺现èæ§ä¿®é£Ÿå ç«ã°ãããªã³åã³ãã®è£œé æ³ |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4962194A (ja) * | 1972-05-10 | 1974-06-17 | ||
| JPS5161640A (en) * | 1974-09-20 | 1976-05-28 | Searle & Co | Koshuyozaino seizoho |
| JPS51144723A (en) * | 1975-05-27 | 1976-12-13 | Yeda Res & Dev | Antiitumor agent |
-
1978
- 1978-12-29 JP JP16138878A patent/JPS5592325A/ja active Granted
-
1979
- 1979-12-19 ZA ZA00796896A patent/ZA796896B/xx unknown
- 1979-12-21 AU AU54144/79A patent/AU518952B2/en not_active Ceased
- 1979-12-28 BE BE6/47054A patent/BE880970A/fr not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4962194A (ja) * | 1972-05-10 | 1974-06-17 | ||
| JPS5161640A (en) * | 1974-09-20 | 1976-05-28 | Searle & Co | Koshuyozaino seizoho |
| JPS51144723A (en) * | 1975-05-27 | 1976-12-13 | Yeda Res & Dev | Antiitumor agent |
Also Published As
| Publication number | Publication date |
|---|---|
| BE880970A (fr) | 1980-06-30 |
| AU518952B2 (en) | 1981-10-29 |
| AU5414479A (en) | 1980-07-03 |
| ZA796896B (en) | 1980-11-26 |
| JPS5592325A (en) | 1980-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4315851A (en) | Pharmaceutical composition having antitumor activity | |
| US4925662A (en) | Anti-tumor substance and process for producing the same | |
| US4093607A (en) | Immunologic chemotherapeutic agents comprising antigen binding dimers covalently bound to drugs | |
| JPH02256700A (ja) | 现èæ¯æ§è¬ç©ã³ã³ãžã¥ã²ãŒã | |
| JP2001500528A (ja) | æ°èŠç³ã¿ã³ãã¯è³ª | |
| EP0620011A1 (en) | Antibody-drug conjugates | |
| JP2017502085A (ja) | ïœïœé£çµãããæäœâè¬ç©ã³ã³ãžã¥ã²ãŒãã®ç²Ÿè£œæ¹æ³ | |
| Rifai et al. | Clearance kinetics and fate of mouse IgA immune complexes prepared with monomeric or dimeric IgA. | |
| Smyth et al. | Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies | |
| JPH02131499A (ja) | 现èæ¯æ§è¬ç©ã³ã³ãžã¥ã²ãŒãããã³ãã®è£œæ³ | |
| KR0184858B1 (ko) | íŽëŠ¬ë¯¹ì ë³µí©ì²Ž | |
| JPH02191300A (ja) | æäœâè¬ç©æ±åäœ | |
| US5672688A (en) | Immunoglobulin Fc fragment bound to an alkylating, antibiotic, or antimetabolic antitum or substance | |
| JPS6254086B2 (ja) | ||
| JPS6256136B2 (ja) | ||
| JPS6256137B2 (ja) | ||
| JPH0133119B2 (ja) | ||
| JPH08509698A (ja) | èçœè³ªè€åäœããããå«ãçµæç©åã³ãã®å»è¬ãšããŠã®çšé | |
| JPH0651643B2 (ja) | 殺现èæ§ä¿®é£Ÿå ç«ã°ãããªã³åã³ãã®è£œé æ¹æ³ | |
| NZ225372A (en) | Immunotoxin composition comprising purified ricin-a-chain species | |
| CA2121990A1 (en) | Antibody-drug conjugates | |
| AU626087B2 (en) | Improved immunotoxin therapies utilizing purified ricin a-chain species | |
| JPH0193538A (ja) | æè «çå€ | |
| EP0539584A1 (en) | Reagent for diagnosing mycoplasma pneumoniae | |
| JPS62142123A (ja) | ããå ç«ã°ãããªã³çµåæè «çå€ |